Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GLGS--STRONG BUY-another Analyst change this morning updated to now a strong buy.
Firms Making Recommendations
JM DUTTON & ASSOCIATES LLC
MOORS & CABOT, INC
this stock will be over $20.00 within a year in my honest opinion based on the developement procedures thats unique to this company.Anyone out there who is familiar with cancer treatments knows what I am talking about.Watch the FDA's fast track procedures and how that works once this is out of phase two.
GlycoGenesys is a drug discovery and development company whose focus is glycomics, an emerging science focused on the chemistry and interactions of carbohydrates and polysaccharides in biological systems. GlycoGenesys is one of only a handful of companies with established intellectual property in glycomics with a glyco-compound that has entered human clinical trials. The initial weakness in the Company's shares was triggered by the March 17 announcement of the placement of a significant portion of the GLGS stock held by Elan Corporation with institutional shareholders, and Elan's April 26 filing for the conversion of its 1.1 million Series C Preferred Shares into common shares. GlycoGenesys continues to make steady progress in the clinical program for GCS-100. We are encouraged that Dr. Cotter is submitting data from his studies with GCS-100 for publication. This is a strong endorsement of the Company's core science and may potentially support a wider range of therapeutic application for GCS-100, thus expanding its market opportunities.
GLGS--taget values of $2.75 short term and $20's plus long term imo--multiple cancers--GS GlycoGenesys Initiates Clinical Trial of GCS-100LE In Multiple Cancers; Company Plans Phase II Trials Once The Maximum Tolerated Dose is Reached
-- GlycoGenesys, Inc. (GLGS, Trade), a biotechnology company focused on carbohydrate drug development, announced today that it has initiated a Phase I dose escalation clinical trial in multiple solid tumor cancer indications evaluating GCS-100LE at Sharp Clinical Oncology Research in San Diego, CA. Dr. Charles Redfern is the Principal Investigator of the study.
GCS-100LE is a substantially ethanol-free formulation of the Company's cancer drug candidate GCS-100(R). Preclinical and toxicology data support dose escalations above the 80 mg/m2 reached in a previous clinical trial, as well as the use of a daily dosing regimen to potentially achieve the maximal biological effect of GCS-100LE in humans. GlycoGenesys developed this formulation of GCS- 100 to avoid potential ethanol-related adverse events at higher dose levels in future trials. Further, GlycoGenesys believes this ethanol removal has increased GCS-100's potential for development as an anticancer therapeutic administered alone or in combination with a variety of cancer therapies.
"We're very pleased with both the financial and operational accomplishments made during the first quarter of 2004. We raised approximately $4.3 million, opened our glycobiology lab, and produced our low-ethanol formulation of GCS-100 for clinical trials," stated John W. Burns, Senior Vice President and Chief Financial Officer of GlycoGenesys, Inc. "The first quarter's net loss applicable to common stock was approximately $845,000 more this year compared to last year primarily due to increased drug production costs, professional fees, preclinical research expenses and the build out and equipment costs of our new lab facility. These expense increases were partially offset by decreases in clinical trial costs for the period. The recent initiation of our Phase I dose escalation trial for GCS-100LE represents one of several corporate milestones planned for this year," added Mr. Burns.
GlycoGenesys, Inc. is a biotechnology company that develops and licenses products based on glycobiology. The Company's human therapeutic product GCS-100, a unique compound to treat cancer, has been evaluated in Phase II(a) human clinical trials for both colorectal and pancreatic cancers. The Company most recently initiated a Phase I dose escalation trial of GCS-100LE at Sharp Clinical Oncology Research in San Diego, California. Further information is available on GlycoGenesys' web site: www.glycogenesys.com.
GlycoGenesys, Inc. is a biotechnology company developing novel drug candidates primarily based on glycobiology. Our product development strategy focuses on therapeutic applications where there is an unmet medical need for life-threatening or debilitating diseases. The Company's lead drug candidate, GCS-100, is a potential treatment for multiple forms of cancer. We plan to advance GCS-100 through the clinical trial process, while selectively building an integrated pipeline of potential new drug candidates.
GLGS--STRONG BUY-another Analyst change this morning updated to now a strong buy.
Firms Making Recommendations
JM DUTTON & ASSOCIATES LLC
MOORS & CABOT, INC
this stock will be over $20.00 within a year in my honest opinion based on the developement procedures thats unique to this company.Anyone out there who is familiar with cancer treatments knows what I am talking about.Watch the FDA's fast track procedures and how that works once this is out of phase two.
GlycoGenesys is a drug discovery and development company whose focus is glycomics, an emerging science focused on the chemistry and interactions of carbohydrates and polysaccharides in biological systems. GlycoGenesys is one of only a handful of companies with established intellectual property in glycomics with a glyco-compound that has entered human clinical trials. The initial weakness in the Company's shares was triggered by the March 17 announcement of the placement of a significant portion of the GLGS stock held by Elan Corporation with institutional shareholders, and Elan's April 26 filing for the conversion of its 1.1 million Series C Preferred Shares into common shares. GlycoGenesys continues to make steady progress in the clinical program for GCS-100. We are encouraged that Dr. Cotter is submitting data from his studies with GCS-100 for publication. This is a strong endorsement of the Company's core science and may potentially support a wider range of therapeutic application for GCS-100, thus expanding its market opportunities.
GLGS--taget values of $2.75 short term and $20's plus long term imo--multiple cancers--GS GlycoGenesys Initiates Clinical Trial of GCS-100LE In Multiple Cancers; Company Plans Phase II Trials Once The Maximum Tolerated Dose is Reached
-- GlycoGenesys, Inc. (GLGS, Trade), a biotechnology company focused on carbohydrate drug development, announced today that it has initiated a Phase I dose escalation clinical trial in multiple solid tumor cancer indications evaluating GCS-100LE at Sharp Clinical Oncology Research in San Diego, CA. Dr. Charles Redfern is the Principal Investigator of the study.
GCS-100LE is a substantially ethanol-free formulation of the Company's cancer drug candidate GCS-100(R). Preclinical and toxicology data support dose escalations above the 80 mg/m2 reached in a previous clinical trial, as well as the use of a daily dosing regimen to potentially achieve the maximal biological effect of GCS-100LE in humans. GlycoGenesys developed this formulation of GCS- 100 to avoid potential ethanol-related adverse events at higher dose levels in future trials. Further, GlycoGenesys believes this ethanol removal has increased GCS-100's potential for development as an anticancer therapeutic administered alone or in combination with a variety of cancer therapies.
"We're very pleased with both the financial and operational accomplishments made during the first quarter of 2004. We raised approximately $4.3 million, opened our glycobiology lab, and produced our low-ethanol formulation of GCS-100 for clinical trials," stated John W. Burns, Senior Vice President and Chief Financial Officer of GlycoGenesys, Inc. "The first quarter's net loss applicable to common stock was approximately $845,000 more this year compared to last year primarily due to increased drug production costs, professional fees, preclinical research expenses and the build out and equipment costs of our new lab facility. These expense increases were partially offset by decreases in clinical trial costs for the period. The recent initiation of our Phase I dose escalation trial for GCS-100LE represents one of several corporate milestones planned for this year," added Mr. Burns.
GlycoGenesys, Inc. is a biotechnology company that develops and licenses products based on glycobiology. The Company's human therapeutic product GCS-100, a unique compound to treat cancer, has been evaluated in Phase II(a) human clinical trials for both colorectal and pancreatic cancers. The Company most recently initiated a Phase I dose escalation trial of GCS-100LE at Sharp Clinical Oncology Research in San Diego, California. Further information is available on GlycoGenesys' web site: www.glycogenesys.com.
GlycoGenesys, Inc. is a biotechnology company developing novel drug candidates primarily based on glycobiology. Our product development strategy focuses on therapeutic applications where there is an unmet medical need for life-threatening or debilitating diseases. The Company's lead drug candidate, GCS-100, is a potential treatment for multiple forms of cancer. We plan to advance GCS-100 through the clinical trial process, while selectively building an integrated pipeline of potential new drug candidates.
harbs--GLGS--STRONG BUY-another Analyst change this morning updated to now a strong buy.
Firms Making Recommendations
JM DUTTON & ASSOCIATES LLC
MOORS & CABOT, INC
this stock will be over $20.00 within a year in my honest opinion based on the developement procedures thats unique to this company.Anyone out there who is familiar with cancer treatments knows what I am talking about.Watch the FDA's fast track procedures and how that works once this is out of phase two.
GlycoGenesys is a drug discovery and development company whose focus is glycomics, an emerging science focused on the chemistry and interactions of carbohydrates and polysaccharides in biological systems. GlycoGenesys is one of only a handful of companies with established intellectual property in glycomics with a glyco-compound that has entered human clinical trials. The initial weakness in the Company's shares was triggered by the March 17 announcement of the placement of a significant portion of the GLGS stock held by Elan Corporation with institutional shareholders, and Elan's April 26 filing for the conversion of its 1.1 million Series C Preferred Shares into common shares. GlycoGenesys continues to make steady progress in the clinical program for GCS-100. We are encouraged that Dr. Cotter is submitting data from his studies with GCS-100 for publication. This is a strong endorsement of the Company's core science and may potentially support a wider range of therapeutic application for GCS-100, thus expanding its market opportunities.
GLGS--taget values of $2.75 short term and $20's plus long term imo--multiple cancers--GS GlycoGenesys Initiates Clinical Trial of GCS-100LE In Multiple Cancers; Company Plans Phase II Trials Once The Maximum Tolerated Dose is Reached
-- GlycoGenesys, Inc. (GLGS, Trade), a biotechnology company focused on carbohydrate drug development, announced today that it has initiated a Phase I dose escalation clinical trial in multiple solid tumor cancer indications evaluating GCS-100LE at Sharp Clinical Oncology Research in San Diego, CA. Dr. Charles Redfern is the Principal Investigator of the study.
GCS-100LE is a substantially ethanol-free formulation of the Company's cancer drug candidate GCS-100(R). Preclinical and toxicology data support dose escalations above the 80 mg/m2 reached in a previous clinical trial, as well as the use of a daily dosing regimen to potentially achieve the maximal biological effect of GCS-100LE in humans. GlycoGenesys developed this formulation of GCS- 100 to avoid potential ethanol-related adverse events at higher dose levels in future trials. Further, GlycoGenesys believes this ethanol removal has increased GCS-100's potential for development as an anticancer therapeutic administered alone or in combination with a variety of cancer therapies.
"We're very pleased with both the financial and operational accomplishments made during the first quarter of 2004. We raised approximately $4.3 million, opened our glycobiology lab, and produced our low-ethanol formulation of GCS-100 for clinical trials," stated John W. Burns, Senior Vice President and Chief Financial Officer of GlycoGenesys, Inc. "The first quarter's net loss applicable to common stock was approximately $845,000 more this year compared to last year primarily due to increased drug production costs, professional fees, preclinical research expenses and the build out and equipment costs of our new lab facility. These expense increases were partially offset by decreases in clinical trial costs for the period. The recent initiation of our Phase I dose escalation trial for GCS-100LE represents one of several corporate milestones planned for this year," added Mr. Burns.
GlycoGenesys, Inc. is a biotechnology company that develops and licenses products based on glycobiology. The Company's human therapeutic product GCS-100, a unique compound to treat cancer, has been evaluated in Phase II(a) human clinical trials for both colorectal and pancreatic cancers. The Company most recently initiated a Phase I dose escalation trial of GCS-100LE at Sharp Clinical Oncology Research in San Diego, California. Further information is available on GlycoGenesys' web site: www.glycogenesys.com.
GlycoGenesys, Inc. is a biotechnology company developing novel drug candidates primarily based on glycobiology. Our product development strategy focuses on therapeutic applications where there is an unmet medical need for life-threatening or debilitating diseases. The Company's lead drug candidate, GCS-100, is a potential treatment for multiple forms of cancer. We plan to advance GCS-100 through the clinical trial process, while selectively building an integrated pipeline of potential new drug candidates.
GLGS--STRONG BUY-another Analyst change this morning updated to now a strong buy.
Firms Making Recommendations
JM DUTTON & ASSOCIATES LLC
MOORS & CABOT, INC
this stock will be over $20.00 within a year in my honest opinion based on the developement procedures thats unique to this company.Anyone out there who is familiar with cancer treatments knows what I am talking about.Watch the FDA's fast track procedures and how that works once this is out of phase two.
GlycoGenesys is a drug discovery and development company whose focus is glycomics, an emerging science focused on the chemistry and interactions of carbohydrates and polysaccharides in biological systems. GlycoGenesys is one of only a handful of companies with established intellectual property in glycomics with a glyco-compound that has entered human clinical trials. The initial weakness in the Company's shares was triggered by the March 17 announcement of the placement of a significant portion of the GLGS stock held by Elan Corporation with institutional shareholders, and Elan's April 26 filing for the conversion of its 1.1 million Series C Preferred Shares into common shares. GlycoGenesys continues to make steady progress in the clinical program for GCS-100. We are encouraged that Dr. Cotter is submitting data from his studies with GCS-100 for publication. This is a strong endorsement of the Company's core science and may potentially support a wider range of therapeutic application for GCS-100, thus expanding its market opportunities.
GLGS--taget values of $2.75 short term and $20's plus long term imo--multiple cancers--GS GlycoGenesys Initiates Clinical Trial of GCS-100LE In Multiple Cancers; Company Plans Phase II Trials Once The Maximum Tolerated Dose is Reached
-- GlycoGenesys, Inc. (GLGS, Trade), a biotechnology company focused on carbohydrate drug development, announced today that it has initiated a Phase I dose escalation clinical trial in multiple solid tumor cancer indications evaluating GCS-100LE at Sharp Clinical Oncology Research in San Diego, CA. Dr. Charles Redfern is the Principal Investigator of the study.
GCS-100LE is a substantially ethanol-free formulation of the Company's cancer drug candidate GCS-100(R). Preclinical and toxicology data support dose escalations above the 80 mg/m2 reached in a previous clinical trial, as well as the use of a daily dosing regimen to potentially achieve the maximal biological effect of GCS-100LE in humans. GlycoGenesys developed this formulation of GCS- 100 to avoid potential ethanol-related adverse events at higher dose levels in future trials. Further, GlycoGenesys believes this ethanol removal has increased GCS-100's potential for development as an anticancer therapeutic administered alone or in combination with a variety of cancer therapies.
"We're very pleased with both the financial and operational accomplishments made during the first quarter of 2004. We raised approximately $4.3 million, opened our glycobiology lab, and produced our low-ethanol formulation of GCS-100 for clinical trials," stated John W. Burns, Senior Vice President and Chief Financial Officer of GlycoGenesys, Inc. "The first quarter's net loss applicable to common stock was approximately $845,000 more this year compared to last year primarily due to increased drug production costs, professional fees, preclinical research expenses and the build out and equipment costs of our new lab facility. These expense increases were partially offset by decreases in clinical trial costs for the period. The recent initiation of our Phase I dose escalation trial for GCS-100LE represents one of several corporate milestones planned for this year," added Mr. Burns.
GlycoGenesys, Inc. is a biotechnology company that develops and licenses products based on glycobiology. The Company's human therapeutic product GCS-100, a unique compound to treat cancer, has been evaluated in Phase II(a) human clinical trials for both colorectal and pancreatic cancers. The Company most recently initiated a Phase I dose escalation trial of GCS-100LE at Sharp Clinical Oncology Research in San Diego, California. Further information is available on GlycoGenesys' web site: www.glycogenesys.com.
GlycoGenesys, Inc. is a biotechnology company developing novel drug candidates primarily based on glycobiology. Our product development strategy focuses on therapeutic applications where there is an unmet medical need for life-threatening or debilitating diseases. The Company's lead drug candidate, GCS-100, is a potential treatment for multiple forms of cancer. We plan to advance GCS-100 through the clinical trial process, while selectively building an integrated pipeline of potential new drug candidates.
OT-GLGS--STRONG BUY-another Analyst change this morning updated to now a strong buy.
Firms Making Recommendations
JM DUTTON & ASSOCIATES LLC
MOORS & CABOT, INC
this stock will be over $20.00 within a year in my honest opinion based on the developement procedures thats unique to this company.Anyone out there who is familiar with cancer treatments knows what I am talking about.Watch the FDA's fast track procedures and how that works once this is out of phase two.
GlycoGenesys is a drug discovery and development company whose focus is glycomics, an emerging science focused on the chemistry and interactions of carbohydrates and polysaccharides in biological systems. GlycoGenesys is one of only a handful of companies with established intellectual property in glycomics with a glyco-compound that has entered human clinical trials. The initial weakness in the Company's shares was triggered by the March 17 announcement of the placement of a significant portion of the GLGS stock held by Elan Corporation with institutional shareholders, and Elan's April 26 filing for the conversion of its 1.1 million Series C Preferred Shares into common shares. GlycoGenesys continues to make steady progress in the clinical program for GCS-100. We are encouraged that Dr. Cotter is submitting data from his studies with GCS-100 for publication. This is a strong endorsement of the Company's core science and may potentially support a wider range of therapeutic application for GCS-100, thus expanding its market opportunities.
GLGS--taget values of $2.75 short term and $20's plus long term imo--multiple cancers--GS GlycoGenesys Initiates Clinical Trial of GCS-100LE In Multiple Cancers; Company Plans Phase II Trials Once The Maximum Tolerated Dose is Reached
-- GlycoGenesys, Inc. (GLGS, Trade), a biotechnology company focused on carbohydrate drug development, announced today that it has initiated a Phase I dose escalation clinical trial in multiple solid tumor cancer indications evaluating GCS-100LE at Sharp Clinical Oncology Research in San Diego, CA. Dr. Charles Redfern is the Principal Investigator of the study.
GCS-100LE is a substantially ethanol-free formulation of the Company's cancer drug candidate GCS-100(R). Preclinical and toxicology data support dose escalations above the 80 mg/m2 reached in a previous clinical trial, as well as the use of a daily dosing regimen to potentially achieve the maximal biological effect of GCS-100LE in humans. GlycoGenesys developed this formulation of GCS- 100 to avoid potential ethanol-related adverse events at higher dose levels in future trials. Further, GlycoGenesys believes this ethanol removal has increased GCS-100's potential for development as an anticancer therapeutic administered alone or in combination with a variety of cancer therapies.
"We're very pleased with both the financial and operational accomplishments made during the first quarter of 2004. We raised approximately $4.3 million, opened our glycobiology lab, and produced our low-ethanol formulation of GCS-100 for clinical trials," stated John W. Burns, Senior Vice President and Chief Financial Officer of GlycoGenesys, Inc. "The first quarter's net loss applicable to common stock was approximately $845,000 more this year compared to last year primarily due to increased drug production costs, professional fees, preclinical research expenses and the build out and equipment costs of our new lab facility. These expense increases were partially offset by decreases in clinical trial costs for the period. The recent initiation of our Phase I dose escalation trial for GCS-100LE represents one of several corporate milestones planned for this year," added Mr. Burns.
GlycoGenesys, Inc. is a biotechnology company that develops and licenses products based on glycobiology. The Company's human therapeutic product GCS-100, a unique compound to treat cancer, has been evaluated in Phase II(a) human clinical trials for both colorectal and pancreatic cancers. The Company most recently initiated a Phase I dose escalation trial of GCS-100LE at Sharp Clinical Oncology Research in San Diego, California. Further information is available on GlycoGenesys' web site: www.glycogenesys.com.
GlycoGenesys, Inc. is a biotechnology company developing novel drug candidates primarily based on glycobiology. Our product development strategy focuses on therapeutic applications where there is an unmet medical need for life-threatening or debilitating diseases. The Company's lead drug candidate, GCS-100, is a potential treatment for multiple forms of cancer. We plan to advance GCS-100 through the clinical trial process, while selectively building an integrated pipeline of potential new drug candidates.
_________________
GLGS--another Analyst change this morning updated to now a strong buy.
Firms Making Recommendations
JM DUTTON & ASSOCIATES LLC
MOORS & CABOT, INC
GLGS.....I expect an after lunch pop,seems the news was late on all the other wires,this could bust a buck in a minute.
GLGS target raised--EL DORADO HILLS, Calif.--(BUSINESS WIRE)--June 7, 2004--J.M. Dutton & Associates continues coverage of GlycoGenesys (Nasdaq:GLGS) with its rating maintained at Strong Speculative Buy and a price target of $2.75. The 7-page report by J.M. Dutton senior analyst Sherry Grisewood, CFA, is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Multex and other leading financial portals.
GlycoGenesys is a drug discovery and development company whose focus is glycomics, an emerging science focused on the chemistry and interactions of carbohydrates and polysaccharides in biological systems. GlycoGenesys is one of only a handful of companies with established intellectual property in glycomics with a glyco-compound that has entered human clinical trials. The initial weakness in the Company's shares was triggered by the March 17 announcement of the placement of a significant portion of the GLGS stock held by Elan Corporation with institutional shareholders, and Elan's April 26 filing for the conversion of its 1.1 million Series C Preferred Shares into common shares. GlycoGenesys continues to make steady progress in the clinical program for GCS-100. We are encouraged that Dr. Cotter is submitting data from his studies with GCS-100 for publication. This is a strong endorsement of the Company's core science and may potentially support a wider range of therapeutic application for GCS-100, thus expanding its market opportunities.
GLGS--taget values of $2.75 short term and $20's plus long term imo--multiple cancers--GS GlycoGenesys Initiates Clinical Trial of GCS-100LE In Multiple Cancers; Company Plans Phase II Trials Once The Maximum Tolerated Dose is Reached
-- GlycoGenesys, Inc. (GLGS, Trade), a biotechnology company focused on carbohydrate drug development, announced today that it has initiated a Phase I dose escalation clinical trial in multiple solid tumor cancer indications evaluating GCS-100LE at Sharp Clinical Oncology Research in San Diego, CA. Dr. Charles Redfern is the Principal Investigator of the study.
GCS-100LE is a substantially ethanol-free formulation of the Company's cancer drug candidate GCS-100(R). Preclinical and toxicology data support dose escalations above the 80 mg/m2 reached in a previous clinical trial, as well as the use of a daily dosing regimen to potentially achieve the maximal biological effect of GCS-100LE in humans. GlycoGenesys developed this formulation of GCS- 100 to avoid potential ethanol-related adverse events at higher dose levels in future trials. Further, GlycoGenesys believes this ethanol removal has increased GCS-100's potential for development as an anticancer therapeutic administered alone or in combination with a variety of cancer therapies.
"We're very pleased with both the financial and operational accomplishments made during the first quarter of 2004. We raised approximately $4.3 million, opened our glycobiology lab, and produced our low-ethanol formulation of GCS-100 for clinical trials," stated John W. Burns, Senior Vice President and Chief Financial Officer of GlycoGenesys, Inc. "The first quarter's net loss applicable to common stock was approximately $845,000 more this year compared to last year primarily due to increased drug production costs, professional fees, preclinical research expenses and the build out and equipment costs of our new lab facility. These expense increases were partially offset by decreases in clinical trial costs for the period. The recent initiation of our Phase I dose escalation trial for GCS-100LE represents one of several corporate milestones planned for this year," added Mr. Burns.
GlycoGenesys, Inc. is a biotechnology company that develops and licenses products based on glycobiology. The Company's human therapeutic product GCS-100, a unique compound to treat cancer, has been evaluated in Phase II(a) human clinical trials for both colorectal and pancreatic cancers. The Company most recently initiated a Phase I dose escalation trial of GCS-100LE at Sharp Clinical Oncology Research in San Diego, California. Further information is available on GlycoGenesys' web site: www.glycogenesys.com.
GlycoGenesys, Inc. is a biotechnology company developing novel drug candidates primarily based on glycobiology. Our product development strategy focuses on therapeutic applications where there is an unmet medical need for life-threatening or debilitating diseases. The Company's lead drug candidate, GCS-100, is a potential treatment for multiple forms of cancer. We plan to advance GCS-100 through the clinical trial process, while selectively building an integrated pipeline of potential new drug candidates.
_________________
GLGS now on the bounce back because of the placement of a significant portion of the GLGS stock held by Elan Corporation with institutional shareholders
GLGS target raised--EL DORADO HILLS, Calif.--(BUSINESS WIRE)--June 7, 2004--J.M. Dutton & Associates continues coverage of GlycoGenesys (Nasdaq:GLGS) with its rating maintained at Strong Speculative Buy and a price target of $2.75. The 7-page report by J.M. Dutton senior analyst Sherry Grisewood, CFA, is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Multex and other leading financial portals.
GlycoGenesys is a drug discovery and development company whose focus is glycomics, an emerging science focused on the chemistry and interactions of carbohydrates and polysaccharides in biological systems. GlycoGenesys is one of only a handful of companies with established intellectual property in glycomics with a glyco-compound that has entered human clinical trials. The initial weakness in the Company's shares was triggered by the March 17 announcement of the placement of a significant portion of the GLGS stock held by Elan Corporation with institutional shareholders, and Elan's April 26 filing for the conversion of its 1.1 million Series C Preferred Shares into common shares. GlycoGenesys continues to make steady progress in the clinical program for GCS-100. We are encouraged that Dr. Cotter is submitting data from his studies with GCS-100 for publication. This is a strong endorsement of the Company's core science and may potentially support a wider range of therapeutic application for GCS-100, thus expanding its market opportunities.
GLGS--taget values of $2.75 short term and $20's plus long term imo--multiple cancers--GS GlycoGenesys Initiates Clinical Trial of GCS-100LE In Multiple Cancers; Company Plans Phase II Trials Once The Maximum Tolerated Dose is Reached
-- GlycoGenesys, Inc. (GLGS, Trade), a biotechnology company focused on carbohydrate drug development, announced today that it has initiated a Phase I dose escalation clinical trial in multiple solid tumor cancer indications evaluating GCS-100LE at Sharp Clinical Oncology Research in San Diego, CA. Dr. Charles Redfern is the Principal Investigator of the study.
GCS-100LE is a substantially ethanol-free formulation of the Company's cancer drug candidate GCS-100(R). Preclinical and toxicology data support dose escalations above the 80 mg/m2 reached in a previous clinical trial, as well as the use of a daily dosing regimen to potentially achieve the maximal biological effect of GCS-100LE in humans. GlycoGenesys developed this formulation of GCS- 100 to avoid potential ethanol-related adverse events at higher dose levels in future trials. Further, GlycoGenesys believes this ethanol removal has increased GCS-100's potential for development as an anticancer therapeutic administered alone or in combination with a variety of cancer therapies.
"We're very pleased with both the financial and operational accomplishments made during the first quarter of 2004. We raised approximately $4.3 million, opened our glycobiology lab, and produced our low-ethanol formulation of GCS-100 for clinical trials," stated John W. Burns, Senior Vice President and Chief Financial Officer of GlycoGenesys, Inc. "The first quarter's net loss applicable to common stock was approximately $845,000 more this year compared to last year primarily due to increased drug production costs, professional fees, preclinical research expenses and the build out and equipment costs of our new lab facility. These expense increases were partially offset by decreases in clinical trial costs for the period. The recent initiation of our Phase I dose escalation trial for GCS-100LE represents one of several corporate milestones planned for this year," added Mr. Burns.
GlycoGenesys, Inc. is a biotechnology company that develops and licenses products based on glycobiology. The Company's human therapeutic product GCS-100, a unique compound to treat cancer, has been evaluated in Phase II(a) human clinical trials for both colorectal and pancreatic cancers. The Company most recently initiated a Phase I dose escalation trial of GCS-100LE at Sharp Clinical Oncology Research in San Diego, California. Further information is available on GlycoGenesys' web site: www.glycogenesys.com.
GlycoGenesys, Inc. is a biotechnology company developing novel drug candidates primarily based on glycobiology. Our product development strategy focuses on therapeutic applications where there is an unmet medical need for life-threatening or debilitating diseases. The Company's lead drug candidate, GCS-100, is a potential treatment for multiple forms of cancer. We plan to advance GCS-100 through the clinical trial process, while selectively building an integrated pipeline of potential new drug candidates.
_________________
UT'ing--NEWS--GLGS target raised--EL DORADO HILLS, Calif.--(BUSINESS WIRE)--June 7, 2004--J.M. Dutton & Associates continues coverage of GlycoGenesys (Nasdaq:GLGS) with its rating maintained at Strong Speculative Buy and a price target of $2.75. The 7-page report by J.M. Dutton senior analyst Sherry Grisewood, CFA, is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Multex and other leading financial portals.
GlycoGenesys is a drug discovery and development company whose focus is glycomics, an emerging science focused on the chemistry and interactions of carbohydrates and polysaccharides in biological systems. GlycoGenesys is one of only a handful of companies with established intellectual property in glycomics with a glyco-compound that has entered human clinical trials. The initial weakness in the Company's shares was triggered by the March 17 announcement of the placement of a significant portion of the GLGS stock held by Elan Corporation with institutional shareholders, and Elan's April 26 filing for the conversion of its 1.1 million Series C Preferred Shares into common shares. GlycoGenesys continues to make steady progress in the clinical program for GCS-100. We are encouraged that Dr. Cotter is submitting data from his studies with GCS-100 for publication. This is a strong endorsement of the Company's core science and may potentially support a wider range of therapeutic application for GCS-100, thus expanding its market opportunities.
GLGS--taget values of $2.75 short term and $20's plus long term imo--multiple cancers--GS GlycoGenesys Initiates Clinical Trial of GCS-100LE In Multiple Cancers; Company Plans Phase II Trials Once The Maximum Tolerated Dose is Reached
-- GlycoGenesys, Inc. (GLGS, Trade), a biotechnology company focused on carbohydrate drug development, announced today that it has initiated a Phase I dose escalation clinical trial in multiple solid tumor cancer indications evaluating GCS-100LE at Sharp Clinical Oncology Research in San Diego, CA. Dr. Charles Redfern is the Principal Investigator of the study.
GCS-100LE is a substantially ethanol-free formulation of the Company's cancer drug candidate GCS-100(R). Preclinical and toxicology data support dose escalations above the 80 mg/m2 reached in a previous clinical trial, as well as the use of a daily dosing regimen to potentially achieve the maximal biological effect of GCS-100LE in humans. GlycoGenesys developed this formulation of GCS- 100 to avoid potential ethanol-related adverse events at higher dose levels in future trials. Further, GlycoGenesys believes this ethanol removal has increased GCS-100's potential for development as an anticancer therapeutic administered alone or in combination with a variety of cancer therapies.
"We're very pleased with both the financial and operational accomplishments made during the first quarter of 2004. We raised approximately $4.3 million, opened our glycobiology lab, and produced our low-ethanol formulation of GCS-100 for clinical trials," stated John W. Burns, Senior Vice President and Chief Financial Officer of GlycoGenesys, Inc. "The first quarter's net loss applicable to common stock was approximately $845,000 more this year compared to last year primarily due to increased drug production costs, professional fees, preclinical research expenses and the build out and equipment costs of our new lab facility. These expense increases were partially offset by decreases in clinical trial costs for the period. The recent initiation of our Phase I dose escalation trial for GCS-100LE represents one of several corporate milestones planned for this year," added Mr. Burns.
GlycoGenesys, Inc. is a biotechnology company that develops and licenses products based on glycobiology. The Company's human therapeutic product GCS-100, a unique compound to treat cancer, has been evaluated in Phase II(a) human clinical trials for both colorectal and pancreatic cancers. The Company most recently initiated a Phase I dose escalation trial of GCS-100LE at Sharp Clinical Oncology Research in San Diego, California. Further information is available on GlycoGenesys' web site: www.glycogenesys.com.
GlycoGenesys, Inc. is a biotechnology company developing novel drug candidates primarily based on glycobiology. Our product development strategy focuses on therapeutic applications where there is an unmet medical need for life-threatening or debilitating diseases. The Company's lead drug candidate, GCS-100, is a potential treatment for multiple forms of cancer. We plan to advance GCS-100 through the clinical trial process, while selectively building an integrated pipeline of potential new drug candidates.
_________________
GLGS target raised--EL DORADO HILLS, Calif.--(BUSINESS WIRE)--June 7, 2004--J.M. Dutton & Associates continues coverage of GlycoGenesys (Nasdaq:GLGS) with its rating maintained at Strong Speculative Buy and a price target of $2.75. The 7-page report by J.M. Dutton senior analyst Sherry Grisewood, CFA, is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Multex and other leading financial portals.
GlycoGenesys is a drug discovery and development company whose focus is glycomics, an emerging science focused on the chemistry and interactions of carbohydrates and polysaccharides in biological systems. GlycoGenesys is one of only a handful of companies with established intellectual property in glycomics with a glyco-compound that has entered human clinical trials. The initial weakness in the Company's shares was triggered by the March 17 announcement of the placement of a significant portion of the GLGS stock held by Elan Corporation with institutional shareholders, and Elan's April 26 filing for the conversion of its 1.1 million Series C Preferred Shares into common shares. GlycoGenesys continues to make steady progress in the clinical program for GCS-100. We are encouraged that Dr. Cotter is submitting data from his studies with GCS-100 for publication. This is a strong endorsement of the Company's core science and may potentially support a wider range of therapeutic application for GCS-100, thus expanding its market opportunities.
GLGS--taget values of $2.75 short term and $20's plus long term imo--multiple cancers--GS GlycoGenesys Initiates Clinical Trial of GCS-100LE In Multiple Cancers; Company Plans Phase II Trials Once The Maximum Tolerated Dose is Reached
-- GlycoGenesys, Inc. (GLGS, Trade), a biotechnology company focused on carbohydrate drug development, announced today that it has initiated a Phase I dose escalation clinical trial in multiple solid tumor cancer indications evaluating GCS-100LE at Sharp Clinical Oncology Research in San Diego, CA. Dr. Charles Redfern is the Principal Investigator of the study.
GCS-100LE is a substantially ethanol-free formulation of the Company's cancer drug candidate GCS-100(R). Preclinical and toxicology data support dose escalations above the 80 mg/m2 reached in a previous clinical trial, as well as the use of a daily dosing regimen to potentially achieve the maximal biological effect of GCS-100LE in humans. GlycoGenesys developed this formulation of GCS- 100 to avoid potential ethanol-related adverse events at higher dose levels in future trials. Further, GlycoGenesys believes this ethanol removal has increased GCS-100's potential for development as an anticancer therapeutic administered alone or in combination with a variety of cancer therapies.
"We're very pleased with both the financial and operational accomplishments made during the first quarter of 2004. We raised approximately $4.3 million, opened our glycobiology lab, and produced our low-ethanol formulation of GCS-100 for clinical trials," stated John W. Burns, Senior Vice President and Chief Financial Officer of GlycoGenesys, Inc. "The first quarter's net loss applicable to common stock was approximately $845,000 more this year compared to last year primarily due to increased drug production costs, professional fees, preclinical research expenses and the build out and equipment costs of our new lab facility. These expense increases were partially offset by decreases in clinical trial costs for the period. The recent initiation of our Phase I dose escalation trial for GCS-100LE represents one of several corporate milestones planned for this year," added Mr. Burns.
GlycoGenesys, Inc. is a biotechnology company that develops and licenses products based on glycobiology. The Company's human therapeutic product GCS-100, a unique compound to treat cancer, has been evaluated in Phase II(a) human clinical trials for both colorectal and pancreatic cancers. The Company most recently initiated a Phase I dose escalation trial of GCS-100LE at Sharp Clinical Oncology Research in San Diego, California. Further information is available on GlycoGenesys' web site: www.glycogenesys.com.
GlycoGenesys, Inc. is a biotechnology company developing novel drug candidates primarily based on glycobiology. Our product development strategy focuses on therapeutic applications where there is an unmet medical need for life-threatening or debilitating diseases. The Company's lead drug candidate, GCS-100, is a potential treatment for multiple forms of cancer. We plan to advance GCS-100 through the clinical trial process, while selectively building an integrated pipeline of potential new drug candidates.
_________________
OT--GLGS target raised--EL DORADO HILLS, Calif.--(BUSINESS WIRE)--June 7, 2004--J.M. Dutton & Associates continues coverage of GlycoGenesys (Nasdaq:GLGS) with its rating maintained at Strong Speculative Buy and a price target of $2.75. The 7-page report by J.M. Dutton senior analyst Sherry Grisewood, CFA, is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Multex and other leading financial portals.
GlycoGenesys is a drug discovery and development company whose focus is glycomics, an emerging science focused on the chemistry and interactions of carbohydrates and polysaccharides in biological systems. GlycoGenesys is one of only a handful of companies with established intellectual property in glycomics with a glyco-compound that has entered human clinical trials. The initial weakness in the Company's shares was triggered by the March 17 announcement of the placement of a significant portion of the GLGS stock held by Elan Corporation with institutional shareholders, and Elan's April 26 filing for the conversion of its 1.1 million Series C Preferred Shares into common shares. GlycoGenesys continues to make steady progress in the clinical program for GCS-100. We are encouraged that Dr. Cotter is submitting data from his studies with GCS-100 for publication. This is a strong endorsement of the Company's core science and may potentially support a wider range of therapeutic application for GCS-100, thus expanding its market opportunities.
GLGS--taget values of $2.75 short term and $20's plus long term imo--multiple cancers--GS GlycoGenesys Initiates Clinical Trial of GCS-100LE In Multiple Cancers; Company Plans Phase II Trials Once The Maximum Tolerated Dose is Reached
-- GlycoGenesys, Inc. (GLGS, Trade), a biotechnology company focused on carbohydrate drug development, announced today that it has initiated a Phase I dose escalation clinical trial in multiple solid tumor cancer indications evaluating GCS-100LE at Sharp Clinical Oncology Research in San Diego, CA. Dr. Charles Redfern is the Principal Investigator of the study.
GCS-100LE is a substantially ethanol-free formulation of the Company's cancer drug candidate GCS-100(R). Preclinical and toxicology data support dose escalations above the 80 mg/m2 reached in a previous clinical trial, as well as the use of a daily dosing regimen to potentially achieve the maximal biological effect of GCS-100LE in humans. GlycoGenesys developed this formulation of GCS- 100 to avoid potential ethanol-related adverse events at higher dose levels in future trials. Further, GlycoGenesys believes this ethanol removal has increased GCS-100's potential for development as an anticancer therapeutic administered alone or in combination with a variety of cancer therapies.
"We're very pleased with both the financial and operational accomplishments made during the first quarter of 2004. We raised approximately $4.3 million, opened our glycobiology lab, and produced our low-ethanol formulation of GCS-100 for clinical trials," stated John W. Burns, Senior Vice President and Chief Financial Officer of GlycoGenesys, Inc. "The first quarter's net loss applicable to common stock was approximately $845,000 more this year compared to last year primarily due to increased drug production costs, professional fees, preclinical research expenses and the build out and equipment costs of our new lab facility. These expense increases were partially offset by decreases in clinical trial costs for the period. The recent initiation of our Phase I dose escalation trial for GCS-100LE represents one of several corporate milestones planned for this year," added Mr. Burns.
GlycoGenesys, Inc. is a biotechnology company that develops and licenses products based on glycobiology. The Company's human therapeutic product GCS-100, a unique compound to treat cancer, has been evaluated in Phase II(a) human clinical trials for both colorectal and pancreatic cancers. The Company most recently initiated a Phase I dose escalation trial of GCS-100LE at Sharp Clinical Oncology Research in San Diego, California. Further information is available on GlycoGenesys' web site: www.glycogenesys.com.
GlycoGenesys, Inc. is a biotechnology company developing novel drug candidates primarily based on glycobiology. Our product development strategy focuses on therapeutic applications where there is an unmet medical need for life-threatening or debilitating diseases. The Company's lead drug candidate, GCS-100, is a potential treatment for multiple forms of cancer. We plan to advance GCS-100 through the clinical trial process, while selectively building an integrated pipeline of potential new drug candidates.
_________________
fdatrader,plenty of room left,the ST price target was raised yesterday to $2.75.
GLGS target raised--EL DORADO HILLS, Calif.--(BUSINESS WIRE)--June 7, 2004--J.M. Dutton & Associates continues coverage of GlycoGenesys (Nasdaq:GLGS) with its rating maintained at Strong Speculative Buy and a price target of $2.75. The 7-page report by J.M. Dutton senior analyst Sherry Grisewood, CFA, is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Multex and other leading financial portals.
GlycoGenesys is a drug discovery and development company whose focus is glycomics, an emerging science focused on the chemistry and interactions of carbohydrates and polysaccharides in biological systems. GlycoGenesys is one of only a handful of companies with established intellectual property in glycomics with a glyco-compound that has entered human clinical trials. The initial weakness in the Company's shares was triggered by the March 17 announcement of the placement of a significant portion of the GLGS stock held by Elan Corporation with institutional shareholders, and Elan's April 26 filing for the conversion of its 1.1 million Series C Preferred Shares into common shares. GlycoGenesys continues to make steady progress in the clinical program for GCS-100. We are encouraged that Dr. Cotter is submitting data from his studies with GCS-100 for publication. This is a strong endorsement of the Company's core science and may potentially support a wider range of therapeutic application for GCS-100, thus expanding its market opportunities.
GLGS--taget values of $2.75 short term and $20's plus long term imo--multiple cancers--GS GlycoGenesys Initiates Clinical Trial of GCS-100LE In Multiple Cancers; Company Plans Phase II Trials Once The Maximum Tolerated Dose is Reached
-- GlycoGenesys, Inc. (GLGS, Trade), a biotechnology company focused on carbohydrate drug development, announced today that it has initiated a Phase I dose escalation clinical trial in multiple solid tumor cancer indications evaluating GCS-100LE at Sharp Clinical Oncology Research in San Diego, CA. Dr. Charles Redfern is the Principal Investigator of the study.
GCS-100LE is a substantially ethanol-free formulation of the Company's cancer drug candidate GCS-100(R). Preclinical and toxicology data support dose escalations above the 80 mg/m2 reached in a previous clinical trial, as well as the use of a daily dosing regimen to potentially achieve the maximal biological effect of GCS-100LE in humans. GlycoGenesys developed this formulation of GCS- 100 to avoid potential ethanol-related adverse events at higher dose levels in future trials. Further, GlycoGenesys believes this ethanol removal has increased GCS-100's potential for development as an anticancer therapeutic administered alone or in combination with a variety of cancer therapies.
"We're very pleased with both the financial and operational accomplishments made during the first quarter of 2004. We raised approximately $4.3 million, opened our glycobiology lab, and produced our low-ethanol formulation of GCS-100 for clinical trials," stated John W. Burns, Senior Vice President and Chief Financial Officer of GlycoGenesys, Inc. "The first quarter's net loss applicable to common stock was approximately $845,000 more this year compared to last year primarily due to increased drug production costs, professional fees, preclinical research expenses and the build out and equipment costs of our new lab facility. These expense increases were partially offset by decreases in clinical trial costs for the period. The recent initiation of our Phase I dose escalation trial for GCS-100LE represents one of several corporate milestones planned for this year," added Mr. Burns.
GlycoGenesys, Inc. is a biotechnology company that develops and licenses products based on glycobiology. The Company's human therapeutic product GCS-100, a unique compound to treat cancer, has been evaluated in Phase II(a) human clinical trials for both colorectal and pancreatic cancers. The Company most recently initiated a Phase I dose escalation trial of GCS-100LE at Sharp Clinical Oncology Research in San Diego, California. Further information is available on GlycoGenesys' web site: www.glycogenesys.com.
GlycoGenesys, Inc. is a biotechnology company developing novel drug candidates primarily based on glycobiology. Our product development strategy focuses on therapeutic applications where there is an unmet medical need for life-threatening or debilitating diseases. The Company's lead drug candidate, GCS-100, is a potential treatment for multiple forms of cancer. We plan to advance GCS-100 through the clinical trial process, while selectively building an integrated pipeline of potential new drug candidates.
_________________
NEWS!! GLGS target raised--EL DORADO HILLS, Calif.--(BUSINESS WIRE)--June 7, 2004--J.M. Dutton & Associates continues coverage of GlycoGenesys (Nasdaq:GLGS) with its rating maintained at Strong Speculative Buy and a price target of $2.75. The 7-page report by J.M. Dutton senior analyst Sherry Grisewood, CFA, is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Multex and other leading financial portals.
GlycoGenesys is a drug discovery and development company whose focus is glycomics, an emerging science focused on the chemistry and interactions of carbohydrates and polysaccharides in biological systems. GlycoGenesys is one of only a handful of companies with established intellectual property in glycomics with a glyco-compound that has entered human clinical trials. The initial weakness in the Company's shares was triggered by the March 17 announcement of the placement of a significant portion of the GLGS stock held by Elan Corporation with institutional shareholders, and Elan's April 26 filing for the conversion of its 1.1 million Series C Preferred Shares into common shares. GlycoGenesys continues to make steady progress in the clinical program for GCS-100. We are encouraged that Dr. Cotter is submitting data from his studies with GCS-100 for publication. This is a strong endorsement of the Company's core science and may potentially support a wider range of therapeutic application for GCS-100, thus expanding its market opportunities.
GLGS--taget values of $2.75 short term and $20's plus long term imo--multiple cancers--GS GlycoGenesys Initiates Clinical Trial of GCS-100LE In Multiple Cancers; Company Plans Phase II Trials Once The Maximum Tolerated Dose is Reached
-- GlycoGenesys, Inc. (GLGS, Trade), a biotechnology company focused on carbohydrate drug development, announced today that it has initiated a Phase I dose escalation clinical trial in multiple solid tumor cancer indications evaluating GCS-100LE at Sharp Clinical Oncology Research in San Diego, CA. Dr. Charles Redfern is the Principal Investigator of the study.
GCS-100LE is a substantially ethanol-free formulation of the Company's cancer drug candidate GCS-100(R). Preclinical and toxicology data support dose escalations above the 80 mg/m2 reached in a previous clinical trial, as well as the use of a daily dosing regimen to potentially achieve the maximal biological effect of GCS-100LE in humans. GlycoGenesys developed this formulation of GCS- 100 to avoid potential ethanol-related adverse events at higher dose levels in future trials. Further, GlycoGenesys believes this ethanol removal has increased GCS-100's potential for development as an anticancer therapeutic administered alone or in combination with a variety of cancer therapies.
"We're very pleased with both the financial and operational accomplishments made during the first quarter of 2004. We raised approximately $4.3 million, opened our glycobiology lab, and produced our low-ethanol formulation of GCS-100 for clinical trials," stated John W. Burns, Senior Vice President and Chief Financial Officer of GlycoGenesys, Inc. "The first quarter's net loss applicable to common stock was approximately $845,000 more this year compared to last year primarily due to increased drug production costs, professional fees, preclinical research expenses and the build out and equipment costs of our new lab facility. These expense increases were partially offset by decreases in clinical trial costs for the period. The recent initiation of our Phase I dose escalation trial for GCS-100LE represents one of several corporate milestones planned for this year," added Mr. Burns.
GlycoGenesys, Inc. is a biotechnology company that develops and licenses products based on glycobiology. The Company's human therapeutic product GCS-100, a unique compound to treat cancer, has been evaluated in Phase II(a) human clinical trials for both colorectal and pancreatic cancers. The Company most recently initiated a Phase I dose escalation trial of GCS-100LE at Sharp Clinical Oncology Research in San Diego, California. Further information is available on GlycoGenesys' web site: www.glycogenesys.com.
GlycoGenesys, Inc. is a biotechnology company developing novel drug candidates primarily based on glycobiology. Our product development strategy focuses on therapeutic applications where there is an unmet medical need for life-threatening or debilitating diseases. The Company's lead drug candidate, GCS-100, is a potential treatment for multiple forms of cancer. We plan to advance GCS-100 through the clinical trial process, while selectively building an integrated pipeline of potential new drug candidates.
NEWS!! GLGS target raised--EL DORADO HILLS, Calif.--(BUSINESS WIRE)--June 7, 2004--J.M. Dutton & Associates continues coverage of GlycoGenesys (Nasdaq:GLGS) with its rating maintained at Strong Speculative Buy and a price target of $2.75. The 7-page report by J.M. Dutton senior analyst Sherry Grisewood, CFA, is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Multex and other leading financial portals.
GlycoGenesys is a drug discovery and development company whose focus is glycomics, an emerging science focused on the chemistry and interactions of carbohydrates and polysaccharides in biological systems. GlycoGenesys is one of only a handful of companies with established intellectual property in glycomics with a glyco-compound that has entered human clinical trials. The initial weakness in the Company's shares was triggered by the March 17 announcement of the placement of a significant portion of the GLGS stock held by Elan Corporation with institutional shareholders, and Elan's April 26 filing for the conversion of its 1.1 million Series C Preferred Shares into common shares. GlycoGenesys continues to make steady progress in the clinical program for GCS-100. We are encouraged that Dr. Cotter is submitting data from his studies with GCS-100 for publication. This is a strong endorsement of the Company's core science and may potentially support a wider range of therapeutic application for GCS-100, thus expanding its market opportunities.
GLGS--taget values of $2.75 short term and $20's plus long term imo--multiple cancers--GS GlycoGenesys Initiates Clinical Trial of GCS-100LE In Multiple Cancers; Company Plans Phase II Trials Once The Maximum Tolerated Dose is Reached
-- GlycoGenesys, Inc. (GLGS, Trade), a biotechnology company focused on carbohydrate drug development, announced today that it has initiated a Phase I dose escalation clinical trial in multiple solid tumor cancer indications evaluating GCS-100LE at Sharp Clinical Oncology Research in San Diego, CA. Dr. Charles Redfern is the Principal Investigator of the study.
GCS-100LE is a substantially ethanol-free formulation of the Company's cancer drug candidate GCS-100(R). Preclinical and toxicology data support dose escalations above the 80 mg/m2 reached in a previous clinical trial, as well as the use of a daily dosing regimen to potentially achieve the maximal biological effect of GCS-100LE in humans. GlycoGenesys developed this formulation of GCS- 100 to avoid potential ethanol-related adverse events at higher dose levels in future trials. Further, GlycoGenesys believes this ethanol removal has increased GCS-100's potential for development as an anticancer therapeutic administered alone or in combination with a variety of cancer therapies.
"We're very pleased with both the financial and operational accomplishments made during the first quarter of 2004. We raised approximately $4.3 million, opened our glycobiology lab, and produced our low-ethanol formulation of GCS-100 for clinical trials," stated John W. Burns, Senior Vice President and Chief Financial Officer of GlycoGenesys, Inc. "The first quarter's net loss applicable to common stock was approximately $845,000 more this year compared to last year primarily due to increased drug production costs, professional fees, preclinical research expenses and the build out and equipment costs of our new lab facility. These expense increases were partially offset by decreases in clinical trial costs for the period. The recent initiation of our Phase I dose escalation trial for GCS-100LE represents one of several corporate milestones planned for this year," added Mr. Burns.
GlycoGenesys, Inc. is a biotechnology company that develops and licenses products based on glycobiology. The Company's human therapeutic product GCS-100, a unique compound to treat cancer, has been evaluated in Phase II(a) human clinical trials for both colorectal and pancreatic cancers. The Company most recently initiated a Phase I dose escalation trial of GCS-100LE at Sharp Clinical Oncology Research in San Diego, California. Further information is available on GlycoGenesys' web site: www.glycogenesys.com.
GlycoGenesys, Inc. is a biotechnology company developing novel drug candidates primarily based on glycobiology. Our product development strategy focuses on therapeutic applications where there is an unmet medical need for life-threatening or debilitating diseases. The Company's lead drug candidate, GCS-100, is a potential treatment for multiple forms of cancer. We plan to advance GCS-100 through the clinical trial process, while selectively building an integrated pipeline of potential new drug candidates.
NEWS!! price target raised for GLGS!!--EL DORADO HILLS, Calif.--(BUSINESS WIRE)--June 7, 2004--J.M. Dutton & Associates continues coverage of GlycoGenesys (Nasdaq:GLGS) with its rating maintained at Strong Speculative Buy and a price target of $2.75. The 7-page report by J.M. Dutton senior analyst Sherry Grisewood, CFA, is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Multex and other leading financial portals.
GlycoGenesys is a drug discovery and development company whose focus is glycomics, an emerging science focused on the chemistry and interactions of carbohydrates and polysaccharides in biological systems. GlycoGenesys is one of only a handful of companies with established intellectual property in glycomics with a glyco-compound that has entered human clinical trials. The initial weakness in the Company's shares was triggered by the March 17 announcement of the placement of a significant portion of the GLGS stock held by Elan Corporation with institutional shareholders, and Elan's April 26 filing for the conversion of its 1.1 million Series C Preferred Shares into common shares. GlycoGenesys continues to make steady progress in the clinical program for GCS-100. We are encouraged that Dr. Cotter is submitting data from his studies with GCS-100 for publication. This is a strong endorsement of the Company's core science and may potentially support a wider range of therapeutic application for GCS-100, thus expanding its market opportunities.
NEWS!!! GLGS target raisde--EL DORADO HILLS, Calif.--(BUSINESS WIRE)--June 7, 2004--J.M. Dutton & Associates continues coverage of GlycoGenesys (Nasdaq:GLGS) with its rating maintained at Strong Speculative Buy and a price target of $2.75. The 7-page report by J.M. Dutton senior analyst Sherry Grisewood, CFA, is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Multex and other leading financial portals.
GlycoGenesys is a drug discovery and development company whose focus is glycomics, an emerging science focused on the chemistry and interactions of carbohydrates and polysaccharides in biological systems. GlycoGenesys is one of only a handful of companies with established intellectual property in glycomics with a glyco-compound that has entered human clinical trials. The initial weakness in the Company's shares was triggered by the March 17 announcement of the placement of a significant portion of the GLGS stock held by Elan Corporation with institutional shareholders, and Elan's April 26 filing for the conversion of its 1.1 million Series C Preferred Shares into common shares. GlycoGenesys continues to make steady progress in the clinical program for GCS-100. We are encouraged that Dr. Cotter is submitting data from his studies with GCS-100 for publication. This is a strong endorsement of the Company's core science and may potentially support a wider range of therapeutic application for GCS-100, thus expanding its market opportunities.
NEWS!! target raised for GLGS--EL DORADO HILLS, Calif.--(BUSINESS WIRE)--June 7, 2004--J.M. Dutton & Associates continues coverage of GlycoGenesys (Nasdaq:GLGS) with its rating maintained at Strong Speculative Buy and a price target of $2.75. The 7-page report by J.M. Dutton senior analyst Sherry Grisewood, CFA, is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Multex and other leading financial portals.
GlycoGenesys is a drug discovery and development company whose focus is glycomics, an emerging science focused on the chemistry and interactions of carbohydrates and polysaccharides in biological systems. GlycoGenesys is one of only a handful of companies with established intellectual property in glycomics with a glyco-compound that has entered human clinical trials. The initial weakness in the Company's shares was triggered by the March 17 announcement of the placement of a significant portion of the GLGS stock held by Elan Corporation with institutional shareholders, and Elan's April 26 filing for the conversion of its 1.1 million Series C Preferred Shares into common shares. GlycoGenesys continues to make steady progress in the clinical program for GCS-100. We are encouraged that Dr. Cotter is submitting data from his studies with GCS-100 for publication. This is a strong endorsement of the Company's core science and may potentially support a wider range of therapeutic application for GCS-100, thus expanding its market opportunities.
OT--GLGS insider holdings increased--
Select a name below for more information. Date Shares Held Change(Shares) % Change(Shares) Value($1000)
CALIFORNIA PUBLIC EM... 3/31/2004 534,800 0 0.00% $332
VANGUARD GROUP INC 3/31/2004 331,054 27,800 9.17% $205
GALLEON MANAGEMENT L... 3/31/2004 200,000 0 0.00% $124
INGALLS & SNYDER LLC 3/31/2004 113,400 0 0.00% $70
MERLIN BIOMED GROUP ... 3/31/2004 100,000 100,000 New $62
Select a name below for more information. Date Shares Held Change(Shares) % Change(Shares) Value($1000)
MERRILL LYNCH & CO I... 3/31/2004 87,201 87,201 New $54
NORTHERN TRUST CORP 3/31/2004 52,875 0 0.00% $33
BEAR STEARNS & CO IN... 3/31/2004 42,205 0 0.00% $26
REYNOLDS CAPITAL MAN... 3/31/2004 37,000 16,000 76.19% $23
BARAKETT TIMOTHY R 3/31/2004 30,000 30,000 New $19
ATTICUS CAPITAL LLC 3/31/2004 30,000 30,000 New $19
DEUTSCHE BANK AG\ 3/31/2004 30,000 11,300 60.43% $19
BARCLAYS GLOBAL INVE... 3/31/2004 26,191 11,030 72.75% $16
WACHOVIA CORP NEW 3/31/2004 15,500 15,500 New $10
GEODE CAPITAL MANAGE... 3/31/2004 13,282 0 0.00% $8
CITIGROUP INC 3/31/2004 12,400 0 0.00% $8
J P MORGAN CHASE & C... 3/31/2004 10,000 0 0.00% $6
HSBC HOLDINGS PLC 3/31/2004 10,000 0 0.00% $6
WELLS FARGO & CO/MN 3/31/2004 1,000 0 0.00% $1
GLGS--target values of $1.50-$2 short term--$20's plus long term imo--multiple cancers--GS GlycoGenesys Initiates Clinical Trial of GCS-100LE In Multiple Cancers; Company Plans Phase II Trials Once The Maximum Tolerated Dose is Reached
-- GlycoGenesys, Inc. (GLGS, Trade), a biotechnology company focused on carbohydrate drug development, announced today that it has initiated a Phase I dose escalation clinical trial in multiple solid tumor cancer indications evaluating GCS-100LE at Sharp Clinical Oncology Research in San Diego, CA. Dr. Charles Redfern is the Principal Investigator of the study.
GCS-100LE is a substantially ethanol-free formulation of the Company's cancer drug candidate GCS-100(R). Preclinical and toxicology data support dose escalations above the 80 mg/m2 reached in a previous clinical trial, as well as the use of a daily dosing regimen to potentially achieve the maximal biological effect of GCS-100LE in humans. GlycoGenesys developed this formulation of GCS- 100 to avoid potential ethanol-related adverse events at higher dose levels in future trials. Further, GlycoGenesys believes this ethanol removal has increased GCS-100's potential for development as an anticancer therapeutic administered alone or in combination with a variety of cancer therapies.
"We're very pleased with both the financial and operational accomplishments made during the first quarter of 2004. We raised approximately $4.3 million, opened our glycobiology lab, and produced our low-ethanol formulation of GCS-100 for clinical trials," stated John W. Burns, Senior Vice President and Chief Financial Officer of GlycoGenesys, Inc. "The first quarter's net loss applicable to common stock was approximately $845,000 more this year compared to last year primarily due to increased drug production costs, professional fees, preclinical research expenses and the build out and equipment costs of our new lab facility. These expense increases were partially offset by decreases in clinical trial costs for the period. The recent initiation of our Phase I dose escalation trial for GCS-100LE represents one of several corporate milestones planned for this year," added Mr. Burns.
GlycoGenesys, Inc. is a biotechnology company that develops and licenses products based on glycobiology. The Company's human therapeutic product GCS-100, a unique compound to treat cancer, has been evaluated in Phase II(a) human clinical trials for both colorectal and pancreatic cancers. The Company most recently initiated a Phase I dose escalation trial of GCS-100LE at Sharp Clinical Oncology Research in San Diego, California. Further information is available on GlycoGenesys' web site: www.glycogenesys.com.
GlycoGenesys, Inc. is a biotechnology company developing novel drug candidates primarily based on glycobiology. Our product development strategy focuses on therapeutic applications where there is an unmet medical need for life-threatening or debilitating diseases. The Company's lead drug candidate, GCS-100, is a potential treatment for multiple forms of cancer. We plan to advance GCS-100 through the clinical trial process, while selectively building an integrated pipeline of potential new drug candidates.
GLGS insider holdings increased--
Select a name below for more information. Date Shares Held Change(Shares) % Change(Shares) Value($1000)
CALIFORNIA PUBLIC EM... 3/31/2004 534,800 0 0.00% $332
VANGUARD GROUP INC 3/31/2004 331,054 27,800 9.17% $205
GALLEON MANAGEMENT L... 3/31/2004 200,000 0 0.00% $124
INGALLS & SNYDER LLC 3/31/2004 113,400 0 0.00% $70
MERLIN BIOMED GROUP ... 3/31/2004 100,000 100,000 New $62
Select a name below for more information. Date Shares Held Change(Shares) % Change(Shares) Value($1000)
MERRILL LYNCH & CO I... 3/31/2004 87,201 87,201 New $54
NORTHERN TRUST CORP 3/31/2004 52,875 0 0.00% $33
BEAR STEARNS & CO IN... 3/31/2004 42,205 0 0.00% $26
REYNOLDS CAPITAL MAN... 3/31/2004 37,000 16,000 76.19% $23
BARAKETT TIMOTHY R 3/31/2004 30,000 30,000 New $19
ATTICUS CAPITAL LLC 3/31/2004 30,000 30,000 New $19
DEUTSCHE BANK AG\ 3/31/2004 30,000 11,300 60.43% $19
BARCLAYS GLOBAL INVE... 3/31/2004 26,191 11,030 72.75% $16
WACHOVIA CORP NEW 3/31/2004 15,500 15,500 New $10
GEODE CAPITAL MANAGE... 3/31/2004 13,282 0 0.00% $8
CITIGROUP INC 3/31/2004 12,400 0 0.00% $8
J P MORGAN CHASE & C... 3/31/2004 10,000 0 0.00% $6
HSBC HOLDINGS PLC 3/31/2004 10,000 0 0.00% $6
WELLS FARGO & CO/MN 3/31/2004 1,000 0 0.00% $1
GLGS--taget values of $1.50-$2 short term--multiple cancers--GS GlycoGenesys Initiates Clinical Trial of GCS-100LE In Multiple Cancers; Company Plans Phase II Trials Once The Maximum Tolerated Dose is Reached
-- GlycoGenesys, Inc. (GLGS, Trade), a biotechnology company focused on carbohydrate drug development, announced today that it has initiated a Phase I dose escalation clinical trial in multiple solid tumor cancer indications evaluating GCS-100LE at Sharp Clinical Oncology Research in San Diego, CA. Dr. Charles Redfern is the Principal Investigator of the study.
GCS-100LE is a substantially ethanol-free formulation of the Company's cancer drug candidate GCS-100(R). Preclinical and toxicology data support dose escalations above the 80 mg/m2 reached in a previous clinical trial, as well as the use of a daily dosing regimen to potentially achieve the maximal biological effect of GCS-100LE in humans. GlycoGenesys developed this formulation of GCS- 100 to avoid potential ethanol-related adverse events at higher dose levels in future trials. Further, GlycoGenesys believes this ethanol removal has increased GCS-100's potential for development as an anticancer therapeutic administered alone or in combination with a variety of cancer therapies.
"We're very pleased with both the financial and operational accomplishments made during the first quarter of 2004. We raised approximately $4.3 million, opened our glycobiology lab, and produced our low-ethanol formulation of GCS-100 for clinical trials," stated John W. Burns, Senior Vice President and Chief Financial Officer of GlycoGenesys, Inc. "The first quarter's net loss applicable to common stock was approximately $845,000 more this year compared to last year primarily due to increased drug production costs, professional fees, preclinical research expenses and the build out and equipment costs of our new lab facility. These expense increases were partially offset by decreases in clinical trial costs for the period. The recent initiation of our Phase I dose escalation trial for GCS-100LE represents one of several corporate milestones planned for this year," added Mr. Burns.
GlycoGenesys, Inc. is a biotechnology company that develops and licenses products based on glycobiology. The Company's human therapeutic product GCS-100, a unique compound to treat cancer, has been evaluated in Phase II(a) human clinical trials for both colorectal and pancreatic cancers. The Company most recently initiated a Phase I dose escalation trial of GCS-100LE at Sharp Clinical Oncology Research in San Diego, California. Further information is available on GlycoGenesys' web site: www.glycogenesys.com.
GlycoGenesys, Inc. is a biotechnology company developing novel drug candidates primarily based on glycobiology. Our product development strategy focuses on therapeutic applications where there is an unmet medical need for life-threatening or debilitating diseases. The Company's lead drug candidate, GCS-100, is a potential treatment for multiple forms of cancer. We plan to advance GCS-100 through the clinical trial process, while selectively building an integrated pipeline of potential new drug candidates.
fdatrader--I believe GLGS will be $20 plus in a year or so and maybe even higher,the rumors of the carbo technique and the FDA have been growing.
GLGS insider holdings increased--
Select a name below for more information. Date Shares Held Change(Shares) % Change(Shares) Value($1000)
CALIFORNIA PUBLIC EM... 3/31/2004 534,800 0 0.00% $332
VANGUARD GROUP INC 3/31/2004 331,054 27,800 9.17% $205
GALLEON MANAGEMENT L... 3/31/2004 200,000 0 0.00% $124
INGALLS & SNYDER LLC 3/31/2004 113,400 0 0.00% $70
MERLIN BIOMED GROUP ... 3/31/2004 100,000 100,000 New $62
Select a name below for more information. Date Shares Held Change(Shares) % Change(Shares) Value($1000)
MERRILL LYNCH & CO I... 3/31/2004 87,201 87,201 New $54
NORTHERN TRUST CORP 3/31/2004 52,875 0 0.00% $33
BEAR STEARNS & CO IN... 3/31/2004 42,205 0 0.00% $26
REYNOLDS CAPITAL MAN... 3/31/2004 37,000 16,000 76.19% $23
BARAKETT TIMOTHY R 3/31/2004 30,000 30,000 New $19
ATTICUS CAPITAL LLC 3/31/2004 30,000 30,000 New $19
DEUTSCHE BANK AG\ 3/31/2004 30,000 11,300 60.43% $19
BARCLAYS GLOBAL INVE... 3/31/2004 26,191 11,030 72.75% $16
WACHOVIA CORP NEW 3/31/2004 15,500 15,500 New $10
GEODE CAPITAL MANAGE... 3/31/2004 13,282 0 0.00% $8
CITIGROUP INC 3/31/2004 12,400 0 0.00% $8
J P MORGAN CHASE & C... 3/31/2004 10,000 0 0.00% $6
HSBC HOLDINGS PLC 3/31/2004 10,000 0 0.00% $6
WELLS FARGO & CO/MN 3/31/2004 1,000 0 0.00% $1
GLGS--taget values of $1.50-$2 short term--multiple cancers--GS GlycoGenesys Initiates Clinical Trial of GCS-100LE In Multiple Cancers; Company Plans Phase II Trials Once The Maximum Tolerated Dose is Reached
-- GlycoGenesys, Inc. (GLGS, Trade), a biotechnology company focused on carbohydrate drug development, announced today that it has initiated a Phase I dose escalation clinical trial in multiple solid tumor cancer indications evaluating GCS-100LE at Sharp Clinical Oncology Research in San Diego, CA. Dr. Charles Redfern is the Principal Investigator of the study.
GCS-100LE is a substantially ethanol-free formulation of the Company's cancer drug candidate GCS-100(R). Preclinical and toxicology data support dose escalations above the 80 mg/m2 reached in a previous clinical trial, as well as the use of a daily dosing regimen to potentially achieve the maximal biological effect of GCS-100LE in humans. GlycoGenesys developed this formulation of GCS- 100 to avoid potential ethanol-related adverse events at higher dose levels in future trials. Further, GlycoGenesys believes this ethanol removal has increased GCS-100's potential for development as an anticancer therapeutic administered alone or in combination with a variety of cancer therapies.
"We're very pleased with both the financial and operational accomplishments made during the first quarter of 2004. We raised approximately $4.3 million, opened our glycobiology lab, and produced our low-ethanol formulation of GCS-100 for clinical trials," stated John W. Burns, Senior Vice President and Chief Financial Officer of GlycoGenesys, Inc. "The first quarter's net loss applicable to common stock was approximately $845,000 more this year compared to last year primarily due to increased drug production costs, professional fees, preclinical research expenses and the build out and equipment costs of our new lab facility. These expense increases were partially offset by decreases in clinical trial costs for the period. The recent initiation of our Phase I dose escalation trial for GCS-100LE represents one of several corporate milestones planned for this year," added Mr. Burns.
GlycoGenesys, Inc. is a biotechnology company that develops and licenses products based on glycobiology. The Company's human therapeutic product GCS-100, a unique compound to treat cancer, has been evaluated in Phase II(a) human clinical trials for both colorectal and pancreatic cancers. The Company most recently initiated a Phase I dose escalation trial of GCS-100LE at Sharp Clinical Oncology Research in San Diego, California. Further information is available on GlycoGenesys' web site: www.glycogenesys.com.
GlycoGenesys, Inc. is a biotechnology company developing novel drug candidates primarily based on glycobiology. Our product development strategy focuses on therapeutic applications where there is an unmet medical need for life-threatening or debilitating diseases. The Company's lead drug candidate, GCS-100, is a potential treatment for multiple forms of cancer. We plan to advance GCS-100 through the clinical trial process, while selectively building an integrated pipeline of potential new drug candidates.
GLGS insider holdings increased--
Select a name below for more information. Date Shares Held Change(Shares) % Change(Shares) Value($1000)
CALIFORNIA PUBLIC EM... 3/31/2004 534,800 0 0.00% $332
VANGUARD GROUP INC 3/31/2004 331,054 27,800 9.17% $205
GALLEON MANAGEMENT L... 3/31/2004 200,000 0 0.00% $124
INGALLS & SNYDER LLC 3/31/2004 113,400 0 0.00% $70
MERLIN BIOMED GROUP ... 3/31/2004 100,000 100,000 New $62
Select a name below for more information. Date Shares Held Change(Shares) % Change(Shares) Value($1000)
MERRILL LYNCH & CO I... 3/31/2004 87,201 87,201 New $54
NORTHERN TRUST CORP 3/31/2004 52,875 0 0.00% $33
BEAR STEARNS & CO IN... 3/31/2004 42,205 0 0.00% $26
REYNOLDS CAPITAL MAN... 3/31/2004 37,000 16,000 76.19% $23
BARAKETT TIMOTHY R 3/31/2004 30,000 30,000 New $19
ATTICUS CAPITAL LLC 3/31/2004 30,000 30,000 New $19
DEUTSCHE BANK AG\ 3/31/2004 30,000 11,300 60.43% $19
BARCLAYS GLOBAL INVE... 3/31/2004 26,191 11,030 72.75% $16
WACHOVIA CORP NEW 3/31/2004 15,500 15,500 New $10
GEODE CAPITAL MANAGE... 3/31/2004 13,282 0 0.00% $8
CITIGROUP INC 3/31/2004 12,400 0 0.00% $8
J P MORGAN CHASE & C... 3/31/2004 10,000 0 0.00% $6
HSBC HOLDINGS PLC 3/31/2004 10,000 0 0.00% $6
WELLS FARGO & CO/MN 3/31/2004 1,000 0 0.00% $1
GLGS--taget values of $1.50-$2 short term--multiple cancers--GS GlycoGenesys Initiates Clinical Trial of GCS-100LE In Multiple Cancers; Company Plans Phase II Trials Once The Maximum Tolerated Dose is Reached
-- GlycoGenesys, Inc. (GLGS, Trade), a biotechnology company focused on carbohydrate drug development, announced today that it has initiated a Phase I dose escalation clinical trial in multiple solid tumor cancer indications evaluating GCS-100LE at Sharp Clinical Oncology Research in San Diego, CA. Dr. Charles Redfern is the Principal Investigator of the study.
GCS-100LE is a substantially ethanol-free formulation of the Company's cancer drug candidate GCS-100(R). Preclinical and toxicology data support dose escalations above the 80 mg/m2 reached in a previous clinical trial, as well as the use of a daily dosing regimen to potentially achieve the maximal biological effect of GCS-100LE in humans. GlycoGenesys developed this formulation of GCS- 100 to avoid potential ethanol-related adverse events at higher dose levels in future trials. Further, GlycoGenesys believes this ethanol removal has increased GCS-100's potential for development as an anticancer therapeutic administered alone or in combination with a variety of cancer therapies.
"We're very pleased with both the financial and operational accomplishments made during the first quarter of 2004. We raised approximately $4.3 million, opened our glycobiology lab, and produced our low-ethanol formulation of GCS-100 for clinical trials," stated John W. Burns, Senior Vice President and Chief Financial Officer of GlycoGenesys, Inc. "The first quarter's net loss applicable to common stock was approximately $845,000 more this year compared to last year primarily due to increased drug production costs, professional fees, preclinical research expenses and the build out and equipment costs of our new lab facility. These expense increases were partially offset by decreases in clinical trial costs for the period. The recent initiation of our Phase I dose escalation trial for GCS-100LE represents one of several corporate milestones planned for this year," added Mr. Burns.
GlycoGenesys, Inc. is a biotechnology company that develops and licenses products based on glycobiology. The Company's human therapeutic product GCS-100, a unique compound to treat cancer, has been evaluated in Phase II(a) human clinical trials for both colorectal and pancreatic cancers. The Company most recently initiated a Phase I dose escalation trial of GCS-100LE at Sharp Clinical Oncology Research in San Diego, California. Further information is available on GlycoGenesys' web site: www.glycogenesys.com.
GlycoGenesys, Inc. is a biotechnology company developing novel drug candidates primarily based on glycobiology. Our product development strategy focuses on therapeutic applications where there is an unmet medical need for life-threatening or debilitating diseases. The Company's lead drug candidate, GCS-100, is a potential treatment for multiple forms of cancer. We plan to advance GCS-100 through the clinical trial process, while selectively building an integrated pipeline of potential new drug candidates.
OT--GLGS insider holdings increased--
Select a name below for more information. Date Shares Held Change(Shares) % Change(Shares) Value($1000)
CALIFORNIA PUBLIC EM... 3/31/2004 534,800 0 0.00% $332
VANGUARD GROUP INC 3/31/2004 331,054 27,800 9.17% $205
GALLEON MANAGEMENT L... 3/31/2004 200,000 0 0.00% $124
INGALLS & SNYDER LLC 3/31/2004 113,400 0 0.00% $70
MERLIN BIOMED GROUP ... 3/31/2004 100,000 100,000 New $62
Select a name below for more information. Date Shares Held Change(Shares) % Change(Shares) Value($1000)
MERRILL LYNCH & CO I... 3/31/2004 87,201 87,201 New $54
NORTHERN TRUST CORP 3/31/2004 52,875 0 0.00% $33
BEAR STEARNS & CO IN... 3/31/2004 42,205 0 0.00% $26
REYNOLDS CAPITAL MAN... 3/31/2004 37,000 16,000 76.19% $23
BARAKETT TIMOTHY R 3/31/2004 30,000 30,000 New $19
ATTICUS CAPITAL LLC 3/31/2004 30,000 30,000 New $19
DEUTSCHE BANK AG\ 3/31/2004 30,000 11,300 60.43% $19
BARCLAYS GLOBAL INVE... 3/31/2004 26,191 11,030 72.75% $16
WACHOVIA CORP NEW 3/31/2004 15,500 15,500 New $10
GEODE CAPITAL MANAGE... 3/31/2004 13,282 0 0.00% $8
CITIGROUP INC 3/31/2004 12,400 0 0.00% $8
J P MORGAN CHASE & C... 3/31/2004 10,000 0 0.00% $6
HSBC HOLDINGS PLC 3/31/2004 10,000 0 0.00% $6
WELLS FARGO & CO/MN 3/31/2004 1,000 0 0.00% $1
GLGS--taget values of $1.50-$2 short term--multiple cancers--GS GlycoGenesys Initiates Clinical Trial of GCS-100LE In Multiple Cancers; Company Plans Phase II Trials Once The Maximum Tolerated Dose is Reached
-- GlycoGenesys, Inc. (GLGS, Trade), a biotechnology company focused on carbohydrate drug development, announced today that it has initiated a Phase I dose escalation clinical trial in multiple solid tumor cancer indications evaluating GCS-100LE at Sharp Clinical Oncology Research in San Diego, CA. Dr. Charles Redfern is the Principal Investigator of the study.
GCS-100LE is a substantially ethanol-free formulation of the Company's cancer drug candidate GCS-100(R). Preclinical and toxicology data support dose escalations above the 80 mg/m2 reached in a previous clinical trial, as well as the use of a daily dosing regimen to potentially achieve the maximal biological effect of GCS-100LE in humans. GlycoGenesys developed this formulation of GCS- 100 to avoid potential ethanol-related adverse events at higher dose levels in future trials. Further, GlycoGenesys believes this ethanol removal has increased GCS-100's potential for development as an anticancer therapeutic administered alone or in combination with a variety of cancer therapies.
"We're very pleased with both the financial and operational accomplishments made during the first quarter of 2004. We raised approximately $4.3 million, opened our glycobiology lab, and produced our low-ethanol formulation of GCS-100 for clinical trials," stated John W. Burns, Senior Vice President and Chief Financial Officer of GlycoGenesys, Inc. "The first quarter's net loss applicable to common stock was approximately $845,000 more this year compared to last year primarily due to increased drug production costs, professional fees, preclinical research expenses and the build out and equipment costs of our new lab facility. These expense increases were partially offset by decreases in clinical trial costs for the period. The recent initiation of our Phase I dose escalation trial for GCS-100LE represents one of several corporate milestones planned for this year," added Mr. Burns.
GlycoGenesys, Inc. is a biotechnology company that develops and licenses products based on glycobiology. The Company's human therapeutic product GCS-100, a unique compound to treat cancer, has been evaluated in Phase II(a) human clinical trials for both colorectal and pancreatic cancers. The Company most recently initiated a Phase I dose escalation trial of GCS-100LE at Sharp Clinical Oncology Research in San Diego, California. Further information is available on GlycoGenesys' web site: www.glycogenesys.com.
GlycoGenesys, Inc. is a biotechnology company developing novel drug candidates primarily based on glycobiology. Our product development strategy focuses on therapeutic applications where there is an unmet medical need for life-threatening or debilitating diseases. The Company's lead drug candidate, GCS-100, is a potential treatment for multiple forms of cancer. We plan to advance GCS-100 through the clinical trial process, while selectively building an integrated pipeline of potential new drug candidates.
GLGS insider holdings increased--
Select a name below for more information. Date Shares Held Change(Shares) % Change(Shares) Value($1000)
CALIFORNIA PUBLIC EM... 3/31/2004 534,800 0 0.00% $332
VANGUARD GROUP INC 3/31/2004 331,054 27,800 9.17% $205
GALLEON MANAGEMENT L... 3/31/2004 200,000 0 0.00% $124
INGALLS & SNYDER LLC 3/31/2004 113,400 0 0.00% $70
MERLIN BIOMED GROUP ... 3/31/2004 100,000 100,000 New $62
Select a name below for more information. Date Shares Held Change(Shares) % Change(Shares) Value($1000)
MERRILL LYNCH & CO I... 3/31/2004 87,201 87,201 New $54
NORTHERN TRUST CORP 3/31/2004 52,875 0 0.00% $33
BEAR STEARNS & CO IN... 3/31/2004 42,205 0 0.00% $26
REYNOLDS CAPITAL MAN... 3/31/2004 37,000 16,000 76.19% $23
BARAKETT TIMOTHY R 3/31/2004 30,000 30,000 New $19
ATTICUS CAPITAL LLC 3/31/2004 30,000 30,000 New $19
DEUTSCHE BANK AG\ 3/31/2004 30,000 11,300 60.43% $19
BARCLAYS GLOBAL INVE... 3/31/2004 26,191 11,030 72.75% $16
WACHOVIA CORP NEW 3/31/2004 15,500 15,500 New $10
GEODE CAPITAL MANAGE... 3/31/2004 13,282 0 0.00% $8
CITIGROUP INC 3/31/2004 12,400 0 0.00% $8
J P MORGAN CHASE & C... 3/31/2004 10,000 0 0.00% $6
HSBC HOLDINGS PLC 3/31/2004 10,000 0 0.00% $6
WELLS FARGO & CO/MN 3/31/2004 1,000 0 0.00% $1
GLGS--taget values of $1.50-$2 short term--multiple cancers--GS GlycoGenesys Initiates Clinical Trial of GCS-100LE In Multiple Cancers; Company Plans Phase II Trials Once The Maximum Tolerated Dose is Reached
-- GlycoGenesys, Inc. (GLGS, Trade), a biotechnology company focused on carbohydrate drug development, announced today that it has initiated a Phase I dose escalation clinical trial in multiple solid tumor cancer indications evaluating GCS-100LE at Sharp Clinical Oncology Research in San Diego, CA. Dr. Charles Redfern is the Principal Investigator of the study.
GCS-100LE is a substantially ethanol-free formulation of the Company's cancer drug candidate GCS-100(R). Preclinical and toxicology data support dose escalations above the 80 mg/m2 reached in a previous clinical trial, as well as the use of a daily dosing regimen to potentially achieve the maximal biological effect of GCS-100LE in humans. GlycoGenesys developed this formulation of GCS- 100 to avoid potential ethanol-related adverse events at higher dose levels in future trials. Further, GlycoGenesys believes this ethanol removal has increased GCS-100's potential for development as an anticancer therapeutic administered alone or in combination with a variety of cancer therapies.
"We're very pleased with both the financial and operational accomplishments made during the first quarter of 2004. We raised approximately $4.3 million, opened our glycobiology lab, and produced our low-ethanol formulation of GCS-100 for clinical trials," stated John W. Burns, Senior Vice President and Chief Financial Officer of GlycoGenesys, Inc. "The first quarter's net loss applicable to common stock was approximately $845,000 more this year compared to last year primarily due to increased drug production costs, professional fees, preclinical research expenses and the build out and equipment costs of our new lab facility. These expense increases were partially offset by decreases in clinical trial costs for the period. The recent initiation of our Phase I dose escalation trial for GCS-100LE represents one of several corporate milestones planned for this year," added Mr. Burns.
GlycoGenesys, Inc. is a biotechnology company that develops and licenses products based on glycobiology. The Company's human therapeutic product GCS-100, a unique compound to treat cancer, has been evaluated in Phase II(a) human clinical trials for both colorectal and pancreatic cancers. The Company most recently initiated a Phase I dose escalation trial of GCS-100LE at Sharp Clinical Oncology Research in San Diego, California. Further information is available on GlycoGenesys' web site: www.glycogenesys.com.
GlycoGenesys, Inc. is a biotechnology company developing novel drug candidates primarily based on glycobiology. Our product development strategy focuses on therapeutic applications where there is an unmet medical need for life-threatening or debilitating diseases. The Company's lead drug candidate, GCS-100, is a potential treatment for multiple forms of cancer. We plan to advance GCS-100 through the clinical trial process, while selectively building an integrated pipeline of potential new drug candidates.
GLGS--taget values of $1.50-$2 short term--multiple cancers--GS GlycoGenesys Initiates Clinical Trial of GCS-100LE In Multiple Cancers; Company Plans Phase II Trials Once The Maximum Tolerated Dose is Reached
-- GlycoGenesys, Inc. (GLGS, Trade), a biotechnology company focused on carbohydrate drug development, announced today that it has initiated a Phase I dose escalation clinical trial in multiple solid tumor cancer indications evaluating GCS-100LE at Sharp Clinical Oncology Research in San Diego, CA. Dr. Charles Redfern is the Principal Investigator of the study.
GCS-100LE is a substantially ethanol-free formulation of the Company's cancer drug candidate GCS-100(R). Preclinical and toxicology data support dose escalations above the 80 mg/m2 reached in a previous clinical trial, as well as the use of a daily dosing regimen to potentially achieve the maximal biological effect of GCS-100LE in humans. GlycoGenesys developed this formulation of GCS- 100 to avoid potential ethanol-related adverse events at higher dose levels in future trials. Further, GlycoGenesys believes this ethanol removal has increased GCS-100's potential for development as an anticancer therapeutic administered alone or in combination with a variety of cancer therapies.
"We're very pleased with both the financial and operational accomplishments made during the first quarter of 2004. We raised approximately $4.3 million, opened our glycobiology lab, and produced our low-ethanol formulation of GCS-100 for clinical trials," stated John W. Burns, Senior Vice President and Chief Financial Officer of GlycoGenesys, Inc. "The first quarter's net loss applicable to common stock was approximately $845,000 more this year compared to last year primarily due to increased drug production costs, professional fees, preclinical research expenses and the build out and equipment costs of our new lab facility. These expense increases were partially offset by decreases in clinical trial costs for the period. The recent initiation of our Phase I dose escalation trial for GCS-100LE represents one of several corporate milestones planned for this year," added Mr. Burns.
GlycoGenesys, Inc. is a biotechnology company that develops and licenses products based on glycobiology. The Company's human therapeutic product GCS-100, a unique compound to treat cancer, has been evaluated in Phase II(a) human clinical trials for both colorectal and pancreatic cancers. The Company most recently initiated a Phase I dose escalation trial of GCS-100LE at Sharp Clinical Oncology Research in San Diego, California. Further information is available on GlycoGenesys' web site: www.glycogenesys.com.
GlycoGenesys, Inc. is a biotechnology company developing novel drug candidates primarily based on glycobiology. Our product development strategy focuses on therapeutic applications where there is an unmet medical need for life-threatening or debilitating diseases. The Company's lead drug candidate, GCS-100, is a potential treatment for multiple forms of cancer. We plan to advance GCS-100 through the clinical trial process, while selectively building an integrated pipeline of potential new drug candidates.
_________________
GLGS--taget values of $1.50-$2 short term--multiple cancers--GS GlycoGenesys Initiates Clinical Trial of GCS-100LE In Multiple Cancers; Company Plans Phase II Trials Once The Maximum Tolerated Dose is Reached
-- GlycoGenesys, Inc. (GLGS, Trade), a biotechnology company focused on carbohydrate drug development, announced today that it has initiated a Phase I dose escalation clinical trial in multiple solid tumor cancer indications evaluating GCS-100LE at Sharp Clinical Oncology Research in San Diego, CA. Dr. Charles Redfern is the Principal Investigator of the study.
GCS-100LE is a substantially ethanol-free formulation of the Company's cancer drug candidate GCS-100(R). Preclinical and toxicology data support dose escalations above the 80 mg/m2 reached in a previous clinical trial, as well as the use of a daily dosing regimen to potentially achieve the maximal biological effect of GCS-100LE in humans. GlycoGenesys developed this formulation of GCS- 100 to avoid potential ethanol-related adverse events at higher dose levels in future trials. Further, GlycoGenesys believes this ethanol removal has increased GCS-100's potential for development as an anticancer therapeutic administered alone or in combination with a variety of cancer therapies.
"We're very pleased with both the financial and operational accomplishments made during the first quarter of 2004. We raised approximately $4.3 million, opened our glycobiology lab, and produced our low-ethanol formulation of GCS-100 for clinical trials," stated John W. Burns, Senior Vice President and Chief Financial Officer of GlycoGenesys, Inc. "The first quarter's net loss applicable to common stock was approximately $845,000 more this year compared to last year primarily due to increased drug production costs, professional fees, preclinical research expenses and the build out and equipment costs of our new lab facility. These expense increases were partially offset by decreases in clinical trial costs for the period. The recent initiation of our Phase I dose escalation trial for GCS-100LE represents one of several corporate milestones planned for this year," added Mr. Burns.
GlycoGenesys, Inc. is a biotechnology company that develops and licenses products based on glycobiology. The Company's human therapeutic product GCS-100, a unique compound to treat cancer, has been evaluated in Phase II(a) human clinical trials for both colorectal and pancreatic cancers. The Company most recently initiated a Phase I dose escalation trial of GCS-100LE at Sharp Clinical Oncology Research in San Diego, California. Further information is available on GlycoGenesys' web site: www.glycogenesys.com.
GlycoGenesys, Inc. is a biotechnology company developing novel drug candidates primarily based on glycobiology. Our product development strategy focuses on therapeutic applications where there is an unmet medical need for life-threatening or debilitating diseases. The Company's lead drug candidate, GCS-100, is a potential treatment for multiple forms of cancer. We plan to advance GCS-100 through the clinical trial process, while selectively building an integrated pipeline of potential new drug candidates.
_________________
GLGS--taget values of $1.50-$2 short term--multiple cancers--GS GlycoGenesys Initiates Clinical Trial of GCS-100LE In Multiple Cancers; Company Plans Phase II Trials Once The Maximum Tolerated Dose is Reached
-- GlycoGenesys, Inc. (GLGS, Trade), a biotechnology company focused on carbohydrate drug development, announced today that it has initiated a Phase I dose escalation clinical trial in multiple solid tumor cancer indications evaluating GCS-100LE at Sharp Clinical Oncology Research in San Diego, CA. Dr. Charles Redfern is the Principal Investigator of the study.
GCS-100LE is a substantially ethanol-free formulation of the Company's cancer drug candidate GCS-100(R). Preclinical and toxicology data support dose escalations above the 80 mg/m2 reached in a previous clinical trial, as well as the use of a daily dosing regimen to potentially achieve the maximal biological effect of GCS-100LE in humans. GlycoGenesys developed this formulation of GCS- 100 to avoid potential ethanol-related adverse events at higher dose levels in future trials. Further, GlycoGenesys believes this ethanol removal has increased GCS-100's potential for development as an anticancer therapeutic administered alone or in combination with a variety of cancer therapies.
"We're very pleased with both the financial and operational accomplishments made during the first quarter of 2004. We raised approximately $4.3 million, opened our glycobiology lab, and produced our low-ethanol formulation of GCS-100 for clinical trials," stated John W. Burns, Senior Vice President and Chief Financial Officer of GlycoGenesys, Inc. "The first quarter's net loss applicable to common stock was approximately $845,000 more this year compared to last year primarily due to increased drug production costs, professional fees, preclinical research expenses and the build out and equipment costs of our new lab facility. These expense increases were partially offset by decreases in clinical trial costs for the period. The recent initiation of our Phase I dose escalation trial for GCS-100LE represents one of several corporate milestones planned for this year," added Mr. Burns.
GlycoGenesys, Inc. is a biotechnology company that develops and licenses products based on glycobiology. The Company's human therapeutic product GCS-100, a unique compound to treat cancer, has been evaluated in Phase II(a) human clinical trials for both colorectal and pancreatic cancers. The Company most recently initiated a Phase I dose escalation trial of GCS-100LE at Sharp Clinical Oncology Research in San Diego, California. Further information is available on GlycoGenesys' web site: www.glycogenesys.com.
GlycoGenesys, Inc. is a biotechnology company developing novel drug candidates primarily based on glycobiology. Our product development strategy focuses on therapeutic applications where there is an unmet medical need for life-threatening or debilitating diseases. The Company's lead drug candidate, GCS-100, is a potential treatment for multiple forms of cancer. We plan to advance GCS-100 through the clinical trial process, while selectively building an integrated pipeline of potential new drug candidates.
_________________
GLGS--taget values of $1.50-$2 short term--multiple cancers--GS GlycoGenesys Initiates Clinical Trial of GCS-100LE In Multiple Cancers; Company Plans Phase II Trials Once The Maximum Tolerated Dose is Reached
-- GlycoGenesys, Inc. (GLGS, Trade), a biotechnology company focused on carbohydrate drug development, announced today that it has initiated a Phase I dose escalation clinical trial in multiple solid tumor cancer indications evaluating GCS-100LE at Sharp Clinical Oncology Research in San Diego, CA. Dr. Charles Redfern is the Principal Investigator of the study.
GCS-100LE is a substantially ethanol-free formulation of the Company's cancer drug candidate GCS-100(R). Preclinical and toxicology data support dose escalations above the 80 mg/m2 reached in a previous clinical trial, as well as the use of a daily dosing regimen to potentially achieve the maximal biological effect of GCS-100LE in humans. GlycoGenesys developed this formulation of GCS- 100 to avoid potential ethanol-related adverse events at higher dose levels in future trials. Further, GlycoGenesys believes this ethanol removal has increased GCS-100's potential for development as an anticancer therapeutic administered alone or in combination with a variety of cancer therapies.
"We're very pleased with both the financial and operational accomplishments made during the first quarter of 2004. We raised approximately $4.3 million, opened our glycobiology lab, and produced our low-ethanol formulation of GCS-100 for clinical trials," stated John W. Burns, Senior Vice President and Chief Financial Officer of GlycoGenesys, Inc. "The first quarter's net loss applicable to common stock was approximately $845,000 more this year compared to last year primarily due to increased drug production costs, professional fees, preclinical research expenses and the build out and equipment costs of our new lab facility. These expense increases were partially offset by decreases in clinical trial costs for the period. The recent initiation of our Phase I dose escalation trial for GCS-100LE represents one of several corporate milestones planned for this year," added Mr. Burns.
GlycoGenesys, Inc. is a biotechnology company that develops and licenses products based on glycobiology. The Company's human therapeutic product GCS-100, a unique compound to treat cancer, has been evaluated in Phase II(a) human clinical trials for both colorectal and pancreatic cancers. The Company most recently initiated a Phase I dose escalation trial of GCS-100LE at Sharp Clinical Oncology Research in San Diego, California. Further information is available on GlycoGenesys' web site: www.glycogenesys.com.
GlycoGenesys, Inc. is a biotechnology company developing novel drug candidates primarily based on glycobiology. Our product development strategy focuses on therapeutic applications where there is an unmet medical need for life-threatening or debilitating diseases. The Company's lead drug candidate, GCS-100, is a potential treatment for multiple forms of cancer. We plan to advance GCS-100 through the clinical trial process, while selectively building an integrated pipeline of potential new drug candidates.
_________________
OT--GLGS--GlycoGenesys Initiates Clinical Trial of GCS-100LE In Multiple Cancers; Company Plans Phase II Trials Once The Maximum Tolerated Dose is Reached ---target values of $1.50-$2 short term--multiple cancers--GS
-- GlycoGenesys, Inc. (GLGS, Trade), a biotechnology company focused on carbohydrate drug development, announced today that it has initiated a Phase I dose escalation clinical trial in multiple solid tumor cancer indications evaluating GCS-100LE at Sharp Clinical Oncology Research in San Diego, CA. Dr. Charles Redfern is the Principal Investigator of the study.
GCS-100LE is a substantially ethanol-free formulation of the Company's cancer drug candidate GCS-100(R). Preclinical and toxicology data support dose escalations above the 80 mg/m2 reached in a previous clinical trial, as well as the use of a daily dosing regimen to potentially achieve the maximal biological effect of GCS-100LE in humans. GlycoGenesys developed this formulation of GCS- 100 to avoid potential ethanol-related adverse events at higher dose levels in future trials. Further, GlycoGenesys believes this ethanol removal has increased GCS-100's potential for development as an anticancer therapeutic administered alone or in combination with a variety of cancer therapies.
"We're very pleased with both the financial and operational accomplishments made during the first quarter of 2004. We raised approximately $4.3 million, opened our glycobiology lab, and produced our low-ethanol formulation of GCS-100 for clinical trials," stated John W. Burns, Senior Vice President and Chief Financial Officer of GlycoGenesys, Inc. "The first quarter's net loss applicable to common stock was approximately $845,000 more this year compared to last year primarily due to increased drug production costs, professional fees, preclinical research expenses and the build out and equipment costs of our new lab facility. These expense increases were partially offset by decreases in clinical trial costs for the period. The recent initiation of our Phase I dose escalation trial for GCS-100LE represents one of several corporate milestones planned for this year," added Mr. Burns.
GlycoGenesys, Inc. is a biotechnology company that develops and licenses products based on glycobiology. The Company's human therapeutic product GCS-100, a unique compound to treat cancer, has been evaluated in Phase II(a) human clinical trials for both colorectal and pancreatic cancers. The Company most recently initiated a Phase I dose escalation trial of GCS-100LE at Sharp Clinical Oncology Research in San Diego, California. Further information is available on GlycoGenesys' web site: www.glycogenesys.com.
ot-GLGS--taget values of $1.50-$2 short term--multiple cancers--GS GlycoGenesys Initiates Clinical Trial of GCS-100LE In Multiple Cancers; Company Plans Phase II Trials Once The Maximum Tolerated Dose is Reached
-- GlycoGenesys, Inc. (GLGS, Trade), a biotechnology company focused on carbohydrate drug development, announced today that it has initiated a Phase I dose escalation clinical trial in multiple solid tumor cancer indications evaluating GCS-100LE at Sharp Clinical Oncology Research in San Diego, CA. Dr. Charles Redfern is the Principal Investigator of the study.
GCS-100LE is a substantially ethanol-free formulation of the Company's cancer drug candidate GCS-100(R). Preclinical and toxicology data support dose escalations above the 80 mg/m2 reached in a previous clinical trial, as well as the use of a daily dosing regimen to potentially achieve the maximal biological effect of GCS-100LE in humans. GlycoGenesys developed this formulation of GCS- 100 to avoid potential ethanol-related adverse events at higher dose levels in future trials. Further, GlycoGenesys believes this ethanol removal has increased GCS-100's potential for development as an anticancer therapeutic administered alone or in combination with a variety of cancer therapies.
"We're very pleased with both the financial and operational accomplishments made during the first quarter of 2004. We raised approximately $4.3 million, opened our glycobiology lab, and produced our low-ethanol formulation of GCS-100 for clinical trials," stated John W. Burns, Senior Vice President and Chief Financial Officer of GlycoGenesys, Inc. "The first quarter's net loss applicable to common stock was approximately $845,000 more this year compared to last year primarily due to increased drug production costs, professional fees, preclinical research expenses and the build out and equipment costs of our new lab facility. These expense increases were partially offset by decreases in clinical trial costs for the period. The recent initiation of our Phase I dose escalation trial for GCS-100LE represents one of several corporate milestones planned for this year," added Mr. Burns.
GlycoGenesys, Inc. is a biotechnology company that develops and licenses products based on glycobiology. The Company's human therapeutic product GCS-100, a unique compound to treat cancer, has been evaluated in Phase II(a) human clinical trials for both colorectal and pancreatic cancers. The Company most recently initiated a Phase I dose escalation trial of GCS-100LE at Sharp Clinical Oncology Research in San Diego, California. Further information is available on GlycoGenesys' web site: www.glycogenesys.com.
GLGS--taget values of $1.50-$2 short term--multiple cancers--GS GlycoGenesys Initiates Clinical Trial of GCS-100LE In Multiple Cancers; Company Plans Phase II Trials Once The Maximum Tolerated Dose is Reached
-- GlycoGenesys, Inc. (GLGS, Trade), a biotechnology company focused on carbohydrate drug development, announced today that it has initiated a Phase I dose escalation clinical trial in multiple solid tumor cancer indications evaluating GCS-100LE at Sharp Clinical Oncology Research in San Diego, CA. Dr. Charles Redfern is the Principal Investigator of the study.
GCS-100LE is a substantially ethanol-free formulation of the Company's cancer drug candidate GCS-100(R). Preclinical and toxicology data support dose escalations above the 80 mg/m2 reached in a previous clinical trial, as well as the use of a daily dosing regimen to potentially achieve the maximal biological effect of GCS-100LE in humans. GlycoGenesys developed this formulation of GCS- 100 to avoid potential ethanol-related adverse events at higher dose levels in future trials. Further, GlycoGenesys believes this ethanol removal has increased GCS-100's potential for development as an anticancer therapeutic administered alone or in combination with a variety of cancer therapies.
"We're very pleased with both the financial and operational accomplishments made during the first quarter of 2004. We raised approximately $4.3 million, opened our glycobiology lab, and produced our low-ethanol formulation of GCS-100 for clinical trials," stated John W. Burns, Senior Vice President and Chief Financial Officer of GlycoGenesys, Inc. "The first quarter's net loss applicable to common stock was approximately $845,000 more this year compared to last year primarily due to increased drug production costs, professional fees, preclinical research expenses and the build out and equipment costs of our new lab facility. These expense increases were partially offset by decreases in clinical trial costs for the period. The recent initiation of our Phase I dose escalation trial for GCS-100LE represents one of several corporate milestones planned for this year," added Mr. Burns.
GlycoGenesys, Inc. is a biotechnology company that develops and licenses products based on glycobiology. The Company's human therapeutic product GCS-100, a unique compound to treat cancer, has been evaluated in Phase II(a) human clinical trials for both colorectal and pancreatic cancers. The Company most recently initiated a Phase I dose escalation trial of GCS-100LE at Sharp Clinical Oncology Research in San Diego, California. Further information is available on GlycoGenesys' web site: www.glycogenesys.com.
a good NAS pick and LT holder to--GLGS--multiple cancers--GS GlycoGenesys Initiates Clinical Trial of GCS-100LE In Multiple Cancers; Company Plans Phase II Trials Once The Maximum Tolerated Dose is Reached
-- GlycoGenesys, Inc. (GLGS, Trade), a biotechnology company focused on carbohydrate drug development, announced today that it has initiated a Phase I dose escalation clinical trial in multiple solid tumor cancer indications evaluating GCS-100LE at Sharp Clinical Oncology Research in San Diego, CA. Dr. Charles Redfern is the Principal Investigator of the study.
GCS-100LE is a substantially ethanol-free formulation of the Company's cancer drug candidate GCS-100(R). Preclinical and toxicology data support dose escalations above the 80 mg/m2 reached in a previous clinical trial, as well as the use of a daily dosing regimen to potentially achieve the maximal biological effect of GCS-100LE in humans. GlycoGenesys developed this formulation of GCS- 100 to avoid potential ethanol-related adverse events at higher dose levels in future trials. Further, GlycoGenesys believes this ethanol removal has increased GCS-100's potential for development as an anticancer therapeutic administered alone or in combination with a variety of cancer therapies.
"We're very pleased with both the financial and operational accomplishments made during the first quarter of 2004. We raised approximately $4.3 million, opened our glycobiology lab, and produced our low-ethanol formulation of GCS-100 for clinical trials," stated John W. Burns, Senior Vice President and Chief Financial Officer of GlycoGenesys, Inc. "The first quarter's net loss applicable to common stock was approximately $845,000 more this year compared to last year primarily due to increased drug production costs, professional fees, preclinical research expenses and the build out and equipment costs of our new lab facility. These expense increases were partially offset by decreases in clinical trial costs for the period. The recent initiation of our Phase I dose escalation trial for GCS-100LE represents one of several corporate milestones planned for this year," added Mr. Burns.
GlycoGenesys, Inc. is a biotechnology company that develops and licenses products based on glycobiology. The Company's human therapeutic product GCS-100, a unique compound to treat cancer, has been evaluated in Phase II(a) human clinical trials for both colorectal and pancreatic cancers. The Company most recently initiated a Phase I dose escalation trial of GCS-100LE at Sharp Clinical Oncology Research in San Diego, California. Further information is available on GlycoGenesys' web site: www.glycogenesys.com.
a good NAS pick--GLGS--multiple cancers--GS GlycoGenesys Initiates Clinical Trial of GCS-100LE In Multiple Cancers; Company Plans Phase II Trials Once The Maximum Tolerated Dose is Reached
-- GlycoGenesys, Inc. (GLGS, Trade), a biotechnology company focused on carbohydrate drug development, announced today that it has initiated a Phase I dose escalation clinical trial in multiple solid tumor cancer indications evaluating GCS-100LE at Sharp Clinical Oncology Research in San Diego, CA. Dr. Charles Redfern is the Principal Investigator of the study.
GCS-100LE is a substantially ethanol-free formulation of the Company's cancer drug candidate GCS-100(R). Preclinical and toxicology data support dose escalations above the 80 mg/m2 reached in a previous clinical trial, as well as the use of a daily dosing regimen to potentially achieve the maximal biological effect of GCS-100LE in humans. GlycoGenesys developed this formulation of GCS- 100 to avoid potential ethanol-related adverse events at higher dose levels in future trials. Further, GlycoGenesys believes this ethanol removal has increased GCS-100's potential for development as an anticancer therapeutic administered alone or in combination with a variety of cancer therapies.
"We're very pleased with both the financial and operational accomplishments made during the first quarter of 2004. We raised approximately $4.3 million, opened our glycobiology lab, and produced our low-ethanol formulation of GCS-100 for clinical trials," stated John W. Burns, Senior Vice President and Chief Financial Officer of GlycoGenesys, Inc. "The first quarter's net loss applicable to common stock was approximately $845,000 more this year compared to last year primarily due to increased drug production costs, professional fees, preclinical research expenses and the build out and equipment costs of our new lab facility. These expense increases were partially offset by decreases in clinical trial costs for the period. The recent initiation of our Phase I dose escalation trial for GCS-100LE represents one of several corporate milestones planned for this year," added Mr. Burns.
GlycoGenesys, Inc. is a biotechnology company that develops and licenses products based on glycobiology. The Company's human therapeutic product GCS-100, a unique compound to treat cancer, has been evaluated in Phase II(a) human clinical trials for both colorectal and pancreatic cancers. The Company most recently initiated a Phase I dose escalation trial of GCS-100LE at Sharp Clinical Oncology Research in San Diego, California. Further information is available on GlycoGenesys' web site: www.glycogenesys.com.
news--TYRIA and TRBY.....eom
NEWS--IVOC---a Federal Government deal thru another housing authority.
MATAWAN, N.J., Jun 02, 2004 (PRIMEZONE via COMTEX) -- iVoice, Inc. (IVOC) , a leader in speech recognition technology, announced today that the Cambridge Housing Authority has installed an IVR application for waiting list information.
The IVR allows clients of the Cambridge Housing Authority to access waiting list information. Callers are prompted for Social Security Number information, which the system verifies by reading it back to the caller. The IVR then gives the caller information regarding the waiting list for which the caller enrolled. For example, the IVR would say, "For the Washington waiting list we are currently placing people who applied before August 10th 2003."
The Cambridge Housing Authority provides both public housing and Section 8 housing to residents of the city. Applicants for housing are placed on a waiting lists based on certain criteria. The waiting list presently has approximately 7000 applicants. The iVoice IVR application is used to allow applicants to call in and easily discover what their position is on any of several waiting lists simply by entering their Social Security Number.
iVoice IVR systems enable callers to make open-ended queries while in the middle of a menu prompt, directing them to the correct information faster. Furthermore, an IVR enabled call center can offer self-service capabilities to callers so they can conduct transactions over the telephone. iVoice's proprietary IVR user interface is able to deliver a powerful solution capable of providing fast, reliable and user-friendly applications to handle transactions such as order fulfillment, obtaining shipping information, obtaining flight information, initiating banking or retail transactions, obtaining product warranty information, confirming reservations, or any other interactive transaction via telephone.
About Cambridge Housing Authority
The Cambridge Housing Authority (CHA) operates a range of federal and state housing programs for low-income elderly, disabled, families and individuals. In addition to programs such as family and elderly public housing and Section 8 certificates and vouchers, the CHA administers a variety of special and innovative housing initiatives. The CHA owns over 2700 units of housing throughout Cambridge.
About iVoice, Inc.
iVoice, Inc. designs, manufactures and markets innovative voice and computer telephony communications systems for businesses and corporate departments. The Interactive Voice Response (IVR) products developed by iVoice allow information in PC databases to be accessed via voice or from a standard touch-tone telephone. iVoice products are designed to be simple for the end user and provide a cohesive system to access messaging systems.
ledrog...I think you missed a few zeros',I believe they have reach the AS limit in stae of corporation and thats at 500 billion shares not million.
skaka....QBID has what 9 billion OS and its high was? PALR going to be 9 billion and hit .016,WNMI? and its high was?? etc.... there are many pennies out here with major OS and FXGO is nothing compared to them yet they trade in the pennies,I am sure you know a few.At these levels you can load up on more for less and when real news pop's on FXGP it will bust up to a dime quick if its supported by the real news.
I agree led,FXGP is about to get some attention imo.
Now, my research tells me that Georal is actually the wrong direction for Finx. Finx should at this time find an alternative "assembler and tester" of the portals, which is basically all Georal is. By doing this, they will boost their margins by 4 or 5 times and Northrop simply wants a portal that does what Finx says it will do according to the DoD certification for ballistics. In case some of you couldn't understand a previous post, an analysis of Georals actual patent filed with USPTO indicates, without a doubt, that their patent is only on an assembled product with original parts from undisclosed vendors. This patent is not enforceable. If you have access to legal, you should run it by them and find out for yourself. A component replacement is all it takes to sidestep it. One wonders how the heck they got it awarded in the first place, but so is the nature of the USPTO and thousands of other patents awarded that seriously raise eyebrows. Risi is totally screwed if Finx replaces them with an alternate supplier.
Finally, the smart card control technology is a huge play that has completely been overlooked by the market and thus is a source of hidden value that active shareholders can unlock. I think Finx Group is an ideal vehicle to be used for a huge roll-up of security system companies including hardware, software and value-added technology. If there is a large equity investment, it will clearly be because the company is going to be acquiring several relevant technologies. Right now, the Georal portal has a critical "add on" that buyers can purchase made by Savoy and ABS. These technologies are in fact the critical component that stands the portal out. If Finx acquired Savoy and ABS, which is a logical possibility, where would Georal stand then? I think we'll see Risi get sued to return his stock to Finx as they look elsewhere.
You should look at the sudden appearance of these bashers as a very positive development in the supply/demand equation of FXGP. The more they bash, the higher this stock will be going.
Watch and learn.
HFT
I called the IR dept. Curt confirmed many of the rumors being posted around here lately:
1. Debt free
2. $8MM in cash- probably for acquisitions
3. doubling revenues this quarter from 1.25 MM to 3MM, and then 5MM next Q
4. no restricted shares O/S
5. Mahoney nearly done dumping his $2.4MM worth of shares to pay himself back for the $2.4MM he lent to IVOC.
6. International patent nearly complete- but he said that international patents usually take longer than domestic patents.
7. IVOC will beat the competition to the international market by 6 months at least, and has a better version of the competitors 'talking pill bottle' because the competitors version requires the pharmacist to enter in the bottle instructions manually, whereas IVOCs will automatically come programed.
* I wonder why with all this good news that IVOC doesn't make a PR confirming it all? I think that if they did the reaction would be explosive. Moreover, I wonder why Mahoney is continuing to sell his shares when a PR of this good news, and upon the completion of the international patent, would almost certainly greatly increase the PPS? That makes no sense to me unless Mahoney doesn't want to stand in the way of the potential run if this news was made available in a PR.
posted by Matt on IVOC board,all this I also have been telling you because I too like many other have been in constant contact with them,this sub is going to launch when least expected.
cut down on med errors (use IVOC tech)
NASHVILLE, Tenn. (Reuters) - President Bush, taking on Democrat John Kerry over health issues, pitched a plan on Thursday to expand the use of technology in medicine -- including a cure for doctors' illegible handwriting.
Bush touted a goal of storing most Americans' medical records in electronic form within 10 years, saying that would reduce paperwork costs and cut down on medical errors.
"Docs are still spending a lot of time writing things on paper. And sometimes it's difficult to read their handwriting," Bush told an audience at Vanderbilt University in the election battleground state of Tennessee.
"Sometimes information gets lost. Sometimes people inadvertently prescribe the wrong drug," he added. "So the fundamental question is: how do we use technology, how do we modernize health care? That's what we're talking about."
In a summary of Bush's health technology initiative, the administration said it was earmarking $100 million toward the effort in the fiscal year 2005 budget, which it said would double funding compared to the year before.
http://www.reuters.com/newsArticle.jhtml?type=topNews&storyID=5280830&src=eDialog/GetContent...